EurekaMag Full Text Articles Chapter 34,335

Piscione, T.D.; Cella, C.; Hu, M.; Rosenblum, N.D. 2002: ALK3 and SMAD4 regulate collecting duct morphogenesis in vivo. Pediatric Research 51(4 Part 2): 53A

Gaussin, V.; Morley, G.; Liu, J.; Cox, L.; Hong, C.; Depre, C.; Myers, D.; Mishina, Y.; Behringer, R.; Hanks, M.; Zwijsen, A.; Huylebroeck, D.; Fishman, G.; Schneider, M.; Burch, J.; Vatner, S. 2004: ALK3 is necessary for atrio-ventricular conduction system development. FASEB Journal 18(4-5): Abstract 307

Gaussin, V.; Liu, J.; Mishina, Y.; Hanks, M.C.; Schneider, M.D.; Burch, J.B. 2003: ALK3-dependent mechanism regulating atrio-ventricular valve development. Circulation 108(17): IV141

Laping, N.J.; Grygielko, E.T.; Thornton, P. 2003: ALK5 inhibition and ACE inhibition reduce matrix markers in diabetic rat kidneys. FASEB Journal 17(4-5): Abstract 569

See, F.; Tzanidis, A.; Krum, H. 2003: ALK5 inhibition attenuates TGFbeta1-induced collagen production by rat cardiac fibroblasts Implications for cardiac remodeling. Circulation 108(17): IV245

Laping, N.J. 2003: ALK5 inhibition in renal disease. Current Opinion in Pharmacology 3(2): 204-208

Owens, J.M.; Hattersley, G.; Lyons, K.; Rosen, V. 2000: ALK6, a type I BMP receptor, is not required for endochondral bone formation. Journal of Bone and Mineral Research 15(Suppl 1): S203

Krauze, A.; Matysiak, M.; Krenke, K. 2001: ALL HRG Experience with modified New York Regimen. Annals of Hematology 80(Suppl 2): S26

Gueller, S.; Beissert, T.; Komor, M.; Schneider, O.; Henschler, R.; Hoelzer, D.; Ottmann, O.G.; Hofmann, W.K.; Ruthardt, M. 2002: ALL-Associated p185 and CML-Associated p210 BCR-ABL Induce a Nearly Identical Gene-Expression Profile In Vivo. Blood 100(11): Abstract No. 1211

Alderman, M.H. 2003: ALLHAT and beyond. American Journal of Hypertension 16(6): 512-514

Lanthier, L.; Nawar, T.; Plante, G.E. 2003: ALLHAT study Towards a unique therapeutic approach of hypertension. M-S (Medecine Sciences) 19(3): 377-380

Ciana, G.; Tamaro, G.; Martini, C.; Ceschel, S.; Cuttini, M.; Bembi, B. 2000: ALP isoenzyme separation in type 1 Gaucher disease. Clinical Chemistry and Laboratory Medicine 38(5): 479-480

Mathews, C.E.; Graser, R.T.; Serreze, D.V.; Leiter, E.H. 1999: ALR/Lt mice beta cell resistance to chemical and autoimmune attack associated with increased anti-oxidant defenses. Diabetes 48(Suppl 1): A450-A451

Couratier, P.; Keita, M.; Magy, L.; Vallat, J.M.chel 2000: ALS CSF is neurotoxic on spinal motoneuron/glial cell cultures. Neurology 54(7 Supp 3): A306

Galasko, D.R.; Plato, C.C.; Garruto, R.M.; Gamst, A.; Craig, U.K.; Torres, J.; Wiederholt, W.C. 2001: ALS and Parkinson-Dementia complex of Guam A 40-year follow-up of a prospective case-control study. Neurology 56(8 Suppl 3): A115-A116

Restivo, D.A.; Bianconi, C.; Ravenni, R.; De Grandis, D. 2000: ALS and myasthenia: An unusual association in a patient treated with riluzole. Muscle and Nerve 23(2): 294-295

McDermott, M.P.; Rowland, L.P. 2001: ALS defeats gabapentin: reflections on another failed treatment. Neurology 56(7): 826-827

Aoki, M.; Nagai, M.; Kato, M.; Itoyama, Y. 2001: ALS models by transgenic animals. No to Shinkei 53(9): 799-807

Anonymous 2004: ALS resistance testing puts situation into perspective. International Pest Control 46(3): 157

Banack, S.A.; Cox, P.A.; Monson, C.S. 2002: ALS-PDC and flying fox declines in Guam Linkage of a human health crisis to wildlife extinction. Ecological Society of America Annual Meeting Abstracts 87: 69

Kruman, I.I.; Camandola, S.; Thellung, S.; Luo, H.; Mattson, M.P. 1999: ALS-linked Cu/Zn-SOD mutation induces mitochondrial dysfunction and disturbance of calcium homeostasis. Society for Neuroscience Abstracts 25(1-2): 1835

Kruman, I.I.; Pedersen, W.; Mattson, M.P. 1999: ALS-linked mutation in human Cu/Zn-SOD enhances vulnerability of motor neurons to excitotoxicity by a mechanism involving increased oxidative stress and perturbed calcium homeostasis. Journal of Neurochemistry 72(Suppl ): S20

Jones, R.; Pembrey, M.; Golding, J.; Alspac Study Team 2001: ALSPAC, a prospective longitudinal population-based study of common outcomes and diseases. Human Mutation 17(4): 334

Dhanji, T.A.; Davies, V.L.; Armon, C.; Moses, D.E.; Britt, W.G.IIi; Graves, M.C.; Forte, D.K.; Sepulveda, L.; Cwik, V.; Lindsey, B.; Shamel, M.; Smith, R.A. 2000: ALSQOL-11-A short, subjective, disease-specific, quality-of-life scale for patients with ALS Sensitivity to change. Neurology 54(7 Supp 3): A344

Panagiotopoulos, S.; Forbes, J.M.; Soulis, T.; Thallas, V.; Long, D.; Jerums, G.; Cooper, M.E. 2000: ALT 946, a novel inhibitor of advanced glycation, prevents albuminuria in experimental diabetes. Journal of the American Society of Nephrology 11(Program and Abstract Issue): 650A

Box, T.D.; Boschert, M.E.; Bowers, J.H.; Hutson, W.R.; Thomason, I.R.; Christiansen, J.E.; Rose, K.; Gaglio, P. 2000: ALT Flare with daily Infergen treatment of chronic hepatitis C. Hepatology 32(4 Pt 2): 566A

Ribeiro, R.M.; Layden, J.E.; Siadat, M.; Layden, T.J.; Perelson, A.S. 2002: ALT dynamics during IFN treatment of HCV infected patients. Hepatology 36(4 Part 2): 293A

Box, T.D.; Boschert, M.E.; Bowers, J.H.; Desautels, S.G.; Hutson, W.R.; Thomason, I.R.; Christiansen, J.E.; Rose, K.; Gaglio, P.J. 2000: ALT elevation with interferon induction therapy A comparison of Intron A vs Infergen. Gastroenterology 118(4 Suppl 2 Pt 2): AASLD A142

Cooksley, W.G. E.; Lai, M.Y.; Piratvisuth, T.; Wang, Y.J.; Mahachai, V.; Chao, Y.C.; Tanwandee, T.; Chutaputti, A.; Chang, W.Y.; Zahm, F.E.; Pluck, N. 2003: ALT flares in patients with HBeAg-positive chronic hepatitis B and treated with either conventional interferon alfa-2a or peginterferon alfa-2a are not necessary for a significant response to therapy. Hepatology 38(4 Suppl 1): 724A

Hann, H.W.L.; Funk, M.L.; Rosenberg, D.M.; Hawley, S.; Davis, R. 2001: ALT normalization and loss of HBV DNA among HBeAg negative hepatitis B patients treated with lamivudine in a clinic setting. Journal of Hepatology 34(Suppl 1): 160

Hudson, V.W.; Chang, H.F.; Mashayekhi, B. 2003: ALTBIB Alternatives to Animal Testing Database. Toxicological Sciences 72(S-1): 219

Mastana, S.S.; Papiha, S.S.; Singh, P.; Singh, M.; Das, K.; Pacynko, A.; Fisher, P.; Das, M.; Malik, N.; Reddy, P. 2002: ALU genetic diversity in British and Indian populations. European Journal of Human Genetics 10(Suppl 1): 186

Mastana, S.S.; Papiha, S.S.; Singh, P.; Das, K.; Pacynko, A.; Fisher, P.; Malik, N.; Das, M.; Reddy, P.H. 2000: ALU genetic diversity in Indian populations. American Journal of Human Genetics 67(4 Suppl 2): 236

Demchyshyn, L.L.; Colantonio, C.M.; Liao, L.; Burrowes, C.; Yang, Z.J. 2001: ALX-0600 A potent glucagon-like peptide-2 receptor agonist. Gastroenterology 120(5 Suppl 1): A 509

Jeppesen, P.B.; Blosch, C.M.; Lopansri, J.B.; Sanguinetti, E.L.; Buchman, A.L.; Scolapio, J.L.; Ziegler, T.R.; Howard, L.; Mortensen, P.B. 2002: ALX-0600, a dipeptidyl peptidase-IV resistant glucagon-like peptide-2 analog, improves intestinal function in short bowel syndrome patients with a jejunostomy. Gastroenterology 122(4 Suppl 1): A-191-A-192

Sorbera, L.A.; Leeson, P.A. 2000: ALX1-11 Treatment of osteoporosis. Drugs of the Future 25(10): 1007-1010

Sun, J. 2003: AM/PM menopausal formula relives menopausal symptoms a pilot study. FASEB Journal 17(4-5): Abstract 692

Kempkes Koch, M.; Fobker, M.; Gerhardt, U.; Suwelack, B.M.; Hohage, H. 2000: AM19 metabolite as a potential biomarker in urine for CsA nephropathy. Journal of the American Society of Nephrology 11(Program and Abstract Issue): 720A

Ramos, A.; Lopez, A.; Talamas, P.; Rosales, J.L. 1999: AM230 of Trypanosoma cruzi induced nitric oxide production by macrophages. American Journal of Tropical Medicine and Hygiene 61(3 Suppl): 263

Villarrubia, V.; Reyes, E.; Alvarez Mon, M. 2002: AM3 normalizes transaminases levels in animal models and in patients with acquired or iatrogenically-induced liver pathologies. Hepatology 36(4 Part 2): 627A

Feld, J.; Heathcote, J. 2002: AMA positive autoimmune hepatitis does not equal AIH/PBC overlap syndrome. Hepatology 36(4 Part 2): 506A

Norton, R.S.; Feng, Z.P.; Evans Stevenson, R.A.; Keizer, D.W.; Yao, S.; Murphy, V.; Coley, A.; Foley, M.; Anders, R.F. 2003: AMA1 from Plasmodium falciparum 3D structure and interactions. Experimental Parasitology 105(1): 10

Zha, Shan; Ferdinandusse, Sacha; Wanders, Ronald J.A.; Luo, Jun; De Marzo, Angelo M.; Isaacs, William B. 2003: AMACR as a new therapeutic target in prostate cancer. Proceedings of the American Association for Cancer Research 44: 192

Gunga, H.C.; Kirsch, K.; Koralewski, E.; Boldt, L.E.; Roecker, L.; Johannes, B.; Fries, D.; Humpeler, E.; Schobersberger, W. 2001: AMAS - 2000 Fluid distribution and tissue thickness changes at moderate altitude in patients with metabolic syndrome. Pfluegers Archiv European Journal of Physiology 441(6 Suppl): R233

Riedmann, B.; Riedmann, G.; Waanders, R.; Fries, D.; Humpeler, E.; Gunga, H.C.; Schobersberger, W. 2001: AMAS - 2000 Wellbeing and cognitive performance of patients with a metabolic syndrome during a three-week stay at moderate altitude. Pfluegers Archiv European Journal of Physiology 441(6 Suppl): R231

Humpeler, E.; Gunga, H.C.; Schobersberger, W. 2001: AMAS-2000 A research project on holiday medicine and altitude acclimatisation. Pfluegers Archiv European Journal of Physiology 441(6 Suppl): R231

Fries, D.; Humpeler, E.; Mittermayr, M.; Klingler, A.; Gunga, H.C.; Jelkmann, W.; Schobersberger, W. 2001: AMAS-2000 Erythropoiesis and iron metabolism in patients with the metabolic syndrome at moderate altitude. Pfluegers Archiv European Journal of Physiology 441(6 Suppl): R232

Lechleitner, M.; Humpeler, E.; Schobersberger, W.; Gunga, H.C.; Hoppichler, F. 2001: AMAS-2000 Metabolic improvement in overweight men exposed to moderate altitude. Pfluegers Archiv European Journal of Physiology 441(6 Suppl): R232

Schmid, P.; Humpeler, E.; Schobersberger, W.; Baumgartner, H.; Hoertnagl, H.; Gunga, H.C.; Klingler, A.; Fries, D.; Spiesberger, R.; Pokan, R. 2001: AMAS-2000 Physical capacity and blood pressure response before, during and 6 weeks after a three weeks stay at moderate altitude in patients with metabolic syndrome. Pfluegers Archiv European Journal of Physiology 441(6 Suppl): R231

Schmid, P.; Humpeler, E.; Schobersberger, W.; Klingler, A.; Hoertnagl, H.; Gunga, H.C.; Fries, D.; Spiesberger, R.; Pokan, R. 2001: AMAS-2000 Twenty-four hour blood pressure and pulse rate monitoring in patients with the metabolic syndrome at moderate altitude. Pfluegers Archiv European Journal of Physiology 441(6 Suppl): R232

Sun, W.; Li, F.; Zhao, K.; Wang, J.; Gao, Y. 2003: AMASS, a bioinformatic tool for validation of SEQUEST search results by automatic screening of its ion maps. Molecular and Cellular Proteomics 2(9): 829

Iwakura, A.; Yamaguchi, J.; Luedemann, C.; Asahara, T.; Losordo, D.; Bridger, G. 2002: AMD-3100, a CXCR4 Antagonist, Augments Incorporation of Bone Marrrow-Derived Eendothelial Progenitor Cells into Sites of Myocardial Neovascularization. Blood 100(11): Abstract No. 1127

Broxmeyer, H.; Cooper, S.; Hangoc, G.; Bridger, G. 2002: AMD-3100, an antagonist of CXCR4, is a potent myeloid progenitor cell mobilizing agent in mouse strains differing in response to G-CSF-induced mobilization, and synergizes with G-CSF in these mice to enhance mobilization. Experimental Hematology (Charlottesville) 30(6 Suppl 1): 45

Flomenberg, N.; Dipersio, J.; Liesveld, J.; Mccarty, J.; Rowley, S.; Vesole, D.; Badel, K.; Calandra, G. 2003: AMD3100+G-CSF hematopoietic progenitor cell mobilization is safe, effective, and superior to mobilization with G-CSF alone. Blood 102(11): 39a

Iwakura, A.; Luedemann, C.; Kusano, K.; Takenaka, H.; Eaton, E.; Bridger, G.; Losordo, D.W. 2003: AMD3100, a CXCR4 antagonist, augments mobilization and incorporation of bone marrow-derived endothelial progenitor cells into sites of myocardial neovascularization. Circulation 108(17): IV159

Broxmeyer, H.E.; Hangoc, G.; Cooper, S.; Li, X.; Bridger, G.; Clapp, D.W.de 2002: AMD3100, an Antagonist of CXCR4 and Mobilizer of Myeloid Progenitor Cells, Is a Potent Mobilizer of Competitive Repopulating Long Term Marrow Self-Renewing Stem Cells in Mice. Blood 100(11): Abstract No. 2397

Devine, S.M.; Liu, F.; Holt, M.; Link, D.; Dipersio, J.F. 2003: AMD3100-mobilized murine hematopoietic stem cells and T-lymphocytes have identical capacity to induce multilineage stem cell engraftment, donor T-cell chimerism and GVHD in mice compared with G-CSF mobilized cells. Blood 102(11): 938a-939a

Giandomenico, C.M. 2003: AMD473, the next generation of orally active platinum anticancer agent. Abstracts of Papers American Chemical Society 226(1-2): INOR 358

Sharov, A.I. 2002: AMETHYST project overview. Berichte zur Polar- und Meeresforschung 413: 55-64

Brenner, B.M. 2003: AMGEN International Prize: the history and future of renoprotection. Kidney International 64(4): 1163-1168

Hair, W.M.; Riley, S.C.; Groome, N.P.; Wu, F.C.W.; Lincoln, G.A. 2001: AMH and inhibin beta as markers of Sertoli cell function during a steroid based hormonal contraceptive regime in men. Journal of Andrology (Suppl): 156

Mccoy, A.K. 2000: AMI in the elderly Variation in treatment choice and outcome. Circulation 102(18): 2; 851

Wu, M.; Zhai, Z.H.; Shu, H.B.n 2002: AMID, an AIF homologous protein, induces caspases-independent apoptosis. Cell Research 12(3-4): 295

Alyea, E.P.; Kim, H.T.; Cutler, C.; Ho, V.; Lee, S.J.; Parik, B.; Windawi, S.; Deangelo, D.; Stone, R.M.; Ritz, J.; Antin, J.H.; Soiffer, R.J. 2003: AML and MDS treated with nonmyeloablative stem cell transplantation Overall and progression free survival comparable to myeloablative transplantation. Blood 102(11): 79a

Lowenberg, B. 2001: AML biology in a clinical perspective. Annals of Hematology 80(Suppl 2): S5

Voliotis, D.; Horn, P.A.; Staib, P.; Diehl, V.; Engert, A. 2001: AML blasts frequently express early B-cell antigen CD79a Is there a need for changing the EGIL classification?. Annals of Hematology 80(Suppl 2): S23

Estey, E.; Beran, M.; Koller, C.; Freireich, E. 1999: AML in elderly patients. Annals of Hematology 78(Suppl 2): S17

Bassan, R.; Marmont, F.; Pogliani, E.; Rossi, G.; Fabris, P.; Porcellini, A.; Musso, M.; Bertoncelli, C.; Sancetta, R.; Di Bona, E.; Intermesoli, T.; Oldani, E.; Rambaldi, A.; Terruzzi, E.; Borlenghi, E.; Crescimanno, A.; Minotto, C.; Chisesi, T.; Coser, P.; Gallo, E.; Barbui, T. 2004: AML in older adults Prognostic improvement by cytogenetic risk group using a risk-adapted, HD-ara-C based multi-cycle program with G-CSF/stem cell support. Annals of Hematology 83(Suppl 1): S13

Buechner, T.; Hiddemann, W.; Woermann, B.; Loeffler, H.; Gassmann, W.; Haferlach, T.; Fonatsch, C.; Haase, D.; Schoch, C.; Hossfeld, D.; Lengfelder, E.; Maschmeyer, G.; Luydwig, W.D.; Sauerland, M.C.; Heinecke, A. 1999: AML in older adults requires intensive rather than attenuated chemotherapy. Annals of Hematology 78(Suppl 2): S17

Lowenberg, B. 2004: AML in older patients Current approach of HOVON-SAKK Cooperative Group. Annals of Hematology 83(Suppl 1): S106

Willman, C.L. 1999: AML in the elderly and secondary AML Biology, prognostic factors, and genetic predisposition. Annals of Hematology 78(Suppl 2): S15

Niederwieser, D.; Hegenbart, U.; Becker, C.; Krahl, R.; Poenisch, W.; Uharek, L.; Al Ali, H.; Moosmann, P.; Gentilini, C.; Wedding, U.; Fiedler, F.; Pasold, R.; Freund, M. 2004: AML studies of the East German Study group - OSHO. Annals of Hematology 83(Suppl 1): S102

Schoch, C.; Kern, W.; Kohlmann, A.; Dugas, M.; Schnittger, S.; Hiddemann, W.; Haferlach, T. 2002: AML with Complex Aberrant Karyotype Can Be Distinguished from All Other AML Subtypes by Gene Expression Profiles and Are Characterized by Higher Expression of Genes Involved in DNA Repair. Blood 100(11): Abstract No. 1204

Schoch, C.; Kern, W.; Schnittger, S.; Kohlmann, A.; Dugas, M.; Hiddemann, W.; Haferlach, T. 2003: AML with complex aberrant karyotype is a distinct entity Evidence provided by chromosome banding analysis, 24-color-FISH, comparative genomic hybridization, gene expression profiling and clinical outcome. Blood 102(11): 375a

Schnittger, S.; Kohlmann, A.; Schoch, C.; Dugas, M.; Kern, W.; Hiddemann, W.; Haferlach, T. 2003: AML with inv /t reveal a specific gene expression signature and dysregulation of many genes involved in megakaryopoiesis and platelet development. Blood 102(11): 215a

Schoch, C.; Haferlach, T.; Schnittger, S.; Kern, W.; Dugas, M.; Hiddemann, W. 2001: AML with recurring chromosome abnormalities as defined in the new WHO-classification Incidence of subgroups, additional genetic abnormalities, FAB subtype and age distribution in an unselected series of 1897 cytogenetically and moleculargenetically analysed AML. Blood 98(11 Part 1): 457a-458a

Choi, S.J.; Oba, T.; Callander, N.S.; Jelinek, D.; Roodman, G.D. 2002: AML-1B down-regulates macrophage inflammatory protein-1alpha expression in multiple myeloma cells. Journal of Bone and Mineral Research 17(Suppl 1): S184-S185

Creutzig, U.; Ritter, J.; Zimmermann, M. 1999: AML-BFM 93 Risk-adapted therapy and randomization in children with AML Preliminary results. Annals of Hematology 78(Suppl 2): S12

Hacihanefioglu, S.; Cirakoglu, A.; Deviren, A.; Kuru, D.; Ongoren, S.; Baslar, Z.; Aktuglu, G. 2001: AML-M3 case report with variant t. Annales de Genetique 44(Suppl 1): s109

Baesecke, J.; Podleschny, M.; Clemens, R.; Schnittger, S.; Truemper, L.; Griesinger, F. 2003: AML-associated genetic aberrations in cord blood-MLL partial tandem duplications, are detectable in stem cells of healthy newborn. Blood 102(11): 844a

De Bont, Eveline S.; Vellenga, Edo; Molema, Grietje; De Leij, Lou H.; Kamps, Willem A. 1999: AML-derived IL-8 production supports angiogenesis. Blood 94(10 Suppl 1 Pt 2): 218b-219b

Niemeyer, C.M.; Duffner, U.; Bender Goetze, C.; Ebell, W.; Hasle, H.; Klingebiehl, T.; Kremens, B.; Nuernberger, W.; Vossen, J.; Zecca, M.; Zintl, F.; Locatelli, F. 2003: AML-type intensive chemotherapy prior to stem cell transplantation does not improve survival in children and adolescents with primary myelodysplastic syndromes. Leukemia Research 27(Suppl 1): S97-S98

Yamaguchi, Y.; Kurokawa, M.; Imai, Y.; Izutsu, K.; Asai, T.; Ichikawa, M.; Yamamoto, G.; Nitta, E.; Yamagata, T.; Sasaki, K.; Mitani, K.; Ogawa, S.; Chiba, S.; Hirai, H. 2004: AML1 is functionally regulated through p300-mediated acetylation on specific lysine residues. Journal of Biological Chemistry 279(15): 15630-15638

Ichikawa, M.; Asai, T.; Saito, T.; Seo, S.; Yamamoto, G.; Yamagata, T.; Yamazaki, I.; Kurokawa, M.; Mitani, K.; Hirai, H. 2002: AML1 Is Required for Megakaryocytic Maturation in Adult Hematopoiesis. Blood 100(11): Abstract No. 488

Licht, J.D. 2001: AML1 and the AML1-ETO fusion protein in the pathogenesis of t AML. Oncogene 20(40): 5660-5679, 10 September

Libermann, T.A.; Pan, Z.; Akbarali, Y.; Hetherington, C.J.; Boltax, J.; Yergeau, D.A.; Zhang, D.E. 1999: AML1 cooperates with B cell-specific activating protein in activation of the B cell-specific BLK gene promoter. Journal of Biological Chemistry 274(35): 24671-24676

Barton, K.; Nucifora, G. 2000: AML1 haploinsufficiency, gene dosage, and the predisposition to acute leukemia. Bioessays: News and Reviews in Molecular Cellular and Developmental Biology 22(3): 214-218

Follows, G.A.; Tagoh, H.; Lefevre, P.; Morgan, G.J.; Bonifer, C. 2003: AML1-ETO acts as a sequence specific transcriptional repressor in vivo by altering the chromatin structure of target genes. British Journal of Haematology 121(Suppl 1): 10

Martinelli, G.; Buonamici, S.; Ottaviani, E.; Giannini, B.; Testoni, N.; Visani, G.; Bonifazi, F.; Terragna, C.; Amabile, M.; Piccaluga, P.P.; Isidori, A.; Malagola, M. 2003: AML1-ETO transcript expression patterns in acute myeloid leukemia patients with t in complete haematological remission. Blood 102(11): 246b

Maki, K.; Yamagata, T.; Asai, T.; Ichikawa, M.; Hirai, H.; Mitani, K. 2003: AML1-Evi-1 knock-in mice show more dysplastic fetal hematopoiesis than AML1-ETO knock-in mice. Blood 102(11): 844a

Wang, Y.; Wang, L.; Lu, S.Y.; Kong, H.; Yuan, W.T.; Jing, Y.E.; Lu, Z.Y.; Chen, S.J.; Chen, Z.; Wang, Z.Y.; Wang, Z.G. 2002: AML1-MTG16 Expression Is Directly Involved in the Development of Acute Myeloid Leukemia. Blood 100(11): Abstract No. 2106

Salomon Nguyen, F.; Coniat, M.B. Le; Pochitaloff, M.L.; Mozziconacci, J.; Berger, R.; Bernard, O.A. 2000: AML1-MTG16 fusion gene in therapy-related acute leukemia with t Two new cases. Leukemia 14(9): 1704-1705

Downing, J.R. 2001: AML1/CBFbeta transcription complex: its role in normal hematopoiesis and leukemia. Leukemia 15(4): 664-665

Basecke, J.; Schwieger, M.; Schiedlmeier, B.; Griesinger, F.; Baum, C.; Wulf, G.; Trumper, L.; Stocking, C. 2002: AML1/ETO Prolongs Survival of Hematopoietic Progenitors but Does Not Abrogate Their Differentiation in NOD/SCID Mice. Blood 100(11): Abstract No. 2119

Liu, S.; Shen, T.; Rush, L.J.; Becknel, B.; Klisovic, M.I.; Whitman, S.P.; Vukosavljevic, T.; Byrd, J.C.; Plass, C.; Marcucci, G. 2003: AML1/ETO associates with DNA methyltransferase 1 in inducing transcriptional repression of the AML1-target gene interleukin-3. Blood 102(11): 218a

Nagel, S.; Krauter, J.; Heidenreich, O.; Nordheim, A.; Ganser, A.; Heil, G. 2001: AML1/ETO mediates repression of CD11c expression in HL60 cells via histone deacetylation. Proceedings of the American Association for Cancer Research 42: 60

Wheeler, J.C.; Wu, Y.; Zelazny, E.T.; Perkins, A.S. 2001: AML1/MDS/Evi-1 cooperation with Bcr-abl in a murine model for CML blast crisis. Blood 98(11 Part 1): 468a-469a

L.S.arza, R.; Sambani, C.; Crescenzi, B.; Matteucci, C.; Martelli, M.F.; Mecucci, C. 2001: AML1/MTG16 fusion gene from a t translocation in treatment induced leukemia after breast cancer Addendum. Haematologica 86(3): 317

Aoki, K.; Shimoda, K.; Matsuda, T.; Numata, A.; Kamezaki, K.; Takase, K.; Haro, T.; Miyamoto, T.; Nagafuji, K.; Gondo, H.; Harada, M. 2002: AML1/MTG8 Leukemic Protein Induces Activation of STAT3. Blood 100(11): Abstract No. 4344

Osato, M.; Yokomizo, T.; Ogawa, M.; Yoshida, H.; Nishikawa, S.I.; Satake, M.; Noda, T.; Ito, Y. 1999: AML1/PEBP2alphaB is essential for the transition from hematogenic endothelial cells to definitive hematopoietic cells. Blood 94(10 Suppl 1 Pt 1): 466a-467a

Bernardin, F.; Collector, M.I.; Friedman, A.D. 2002: AML1/RUNX1 Levels Increase during the Late G1/Early S Cell Cycle Phases and Stimulate S Phase Entry. Blood 100(11): Abstract No. 2085

Bernardin, F.; Collector, M.; Friedman, A.D. 2003: AML1/RUNX1 protein levels increase during the late G1/early S cell cycle phases. Blood 102(11): 847a

Dupret, C.; Asnafi, V.; Libura, M.; Millien, C.; Delabesse, E.; Valensi, F.; Beldjord, K.; Macintyre, E. 2003: AMLs with MLL translocation can be separated into those with T and B lymphoid potential on the basis of their TCR and IgH genetic profiles. Blood 102(11): 21a

Hourdin,F.; Musat,I.; Guichard,F.; Ruti,P.M.; Favot,F.; Filiberti,M.A.; Pham,M.; Grandpeix,J.Y.; Polcher,J.; Marquet,P.; Boone,A.; Lafore,J.P.; Redelsperger,J.L.; Dell'Aquila,A.; Doval,T.L.; Traore,A.K.; Gallee,H. 2010: AMMA-model intercomparison project. Bulletin Of The American Meteorological Society: 1, 95-104

Clark, K.L.; Merkel, L.; Zannikos, P.; Kelley, M.F.; Boutouyrie, B.; Perrone, M.H. 2000: AMP 579, a novel adenosine agonist for the treatment of acute myocardial infarction. Cardiovascular Drug Reviews 18(3): 183-210

Hattori,N.; Nomoto,H.; Fukumitsu,H.; Mishima,S.; Furukawa,S. 2010: AMP N1-oxide, a unique compound of royal jelly, induces neurite outgrowth from PC12 cells via signaling by protein kinase A independent of that by mitogen-activated protein kinase. Evidence Based Complementary And Alternative Medicine: 1, 63-68

Kemp, B.E.; Stapleton, D.I.; Mitchelhill, K.I.; Witters, L.A. 2000: AMP activated protein kinase. Official Gazette of the United States Patent and Trademark Office Patents 1238(4)

Culmsee, C.; Monnig, J.; Kemp, B.E.; Mattson, M.P. 2000: AMP activated protein kinase protects hippocampal neurons against metabolic, excitotoxic and oxidative insults. European Journal of Neuroscience 12(Suppl 11): 231

Bjelakovic, G.; Nagorni, A.; Bjelakovic, M. 2002: AMP deaminase activity and urate levels in liver cirrhosis. Journal of Hepatology 36(Suppl 1): 46

Bjelakovic, G.B.; Benedeto Stojanov, D.; Bjelakovic, M.; Bjelakovic, G. 2000: AMP deaminase activity and urate levels in sera and ascitic fluid of cirrhotic patients as biochemical markers of tissue hypoxia. Journal of Hepatology 32(Suppl 2): 153

Zarzeczny, R.; Terjung, R.L. 1999: AMP deaminase activity in muscle during mild contraction conditions following activation of AMP-activated protein kinase. Medicine and Science in Sports and Exercise 31(5 Suppl): S278

Ching, L.L.; Williams, A.J.; Sitsapesan, R. 1999: AMP is an agonist with low efficacy at the ATP sites on the sheep cardiac ryanodine receptor. Biophysical Journal 76(1 Part 2): A376

Murphy, R.T.; Mogensen, J.; Bahl, A.; Kobu, T.; Holton, J.; Elliott, P.M.; Mcgarry, K.; Mckenna, W.J. 2004: AMP kinase disease in hypertrophic cardiomyopathy Evidence for a multisystem storage disorder. Journal of the American College of Cardiology 43(5 Suppl A): 166A

Rubin, L.J.; Jones, A.W.; Magliola, L.; Price, E.M. 2001: AMP kinase in vascular smooth muscle. FASEB Journal 15(4): A457

Nagata, D.; Walsh, K. 2002: AMP kinase inhibits endothelial cell apoptosis through activation of the PI3K/Atk axis. Circulation 106(19): II304

Holmes, B.; Lang, D.; Mu, J.; Birnbaum, M.; Dohm, G.L.nis 2003: AMP kinase is not a major regulator of GLUT4 gene expression in response to exercise. Diabetes 52(Suppl 1): A12

Sorbera, L.A.; Martin, L.; Leeson, P.A.; Castaner, J. 2000: AMP-579 Treatment of acute myocardial infarction adenosine A1/A2A agonist RPR-100579. Drugs of the Future 25(9): 900-906

Palnitkar, S.S.; Herman, K.; Parness, J. 1999: AMP-PCP enhances dantrolene binding to skeletal muscle sarcoplasmic reticulum. Biophysical Journal 76(1 Part 2): A471

Fleming, I.; Schulz, C.; Kempter, I.; Fichtlscherer, B.; Fisslthaler, B.; Busse, R. 2000: AMP-activated kinase , Akt and Hsp90 regulate the insulin-induced activation of the nitric oxide synthase in human platelets. Nitric Oxide 4(3): 180

Hallows, K.R.; Grieser, H.J.; Bruns, J.R.; Carattino, M.D.; Kleyman, T.R.; Johnson, J.P.; Edinger, R.S. 2003: AMP-activated kinase modulates epithelial Na+ channel activity in oocytes and polarized mouse CCD cells. Journal of the American Society of Nephrology 14(Abstracts Issue): 81A

Hardie, D.Grahame 2001: AMP-activated protein kinase The key sensor of cellular energy charge. Journal of Molecular and Cellular Cardiology 33(6): A146

Yagihashi, N.; Cacicedo, J.; Tsao, T.S.; Lodish, H.; Ruderman, N.; Ido, Y. 2003: AMP-activated protein kinase activator, AICAR and adiponectin inhibit vascular endothelial growth factor induced vascular cell adhesion molecule -1 expression in human aortic endothelial cells. Diabetes 52(Suppl 1): A182

Saranchuk, R.; Altarejos, J.; Lopaschuk, G.D.; Gallo, M.E.; Putman, C.T. 2002: AMP-activated protein kinase activity is greatest in muscles composed of fast-twitch type-IId/x and -IIb fibers. FASEB Journal 16(5): A760

Hemingway, C.J.; Munday, M.R. 1999: AMP-activated protein kinase in rat brain. Journal of Pharmacy and Pharmacology 51(Suppl ): 170

Hallows, K.R.; Mccane, J.E.; Ragburam, V.; Foskett, J.K.vin 2002: AMP-activated protein kinase inhibits CFTR activity by effects on channel gating. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 22A

Graham, M.L.; Setola, V.; Massillon, D. 2001: AMP-activated protein kinase mimics insulins repression of glucose-stimulation of glucose-6-phosphatase gene expression. Diabetes 50(Suppl 2): A287

Um, J.-H.; Park, S.-J.; Kang, H.; Yang, S.; Foretz, M.; McBurney, M.W.; Kim, M.K.; Viollet, B.; Chung, J.H. 2010: AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 59(3): 554-563

Zhou, G.; Li, Y.; Chen, Y.; Shen, X.; Doebber, T.; Moller, D.E. 2001: AMP-kinase mediates metabolic effects of metformin. Diabetes 50(Suppl 2): A274

Shah, A.G.; Ren, H.; Musch, M.W.; Walsh Reitz, M.M.; Hart, J.A.; Hogan, N.; Martin, T.E.; Toback, F.G.; Chang, E.B. 2001: AMP18, a novel, cytoprotective, wound-healing, antral mucosal peptide Distribution and potential role in the development of NSAID-induced gastric injury. Gastroenterology 120(5 Suppl 1): A 147

Auberson, Y.P. 2000: AMP397A Novel, broad-spectrum anticonvulsant with potential benefit for therapy-resistant epileptic patients. Abstracts of Papers American Chemical Society 219(1-2): MEDI 14

Xu, Z.; Cohen, M.V.; Heusch, G.; Downey, J.M. 2000: AMP579 at reperfusion limits infarct size in crystalloid-perfused rabbit hearts. Circulation 102(18): 2; 272

Nakamura, M.; Zhao, Z.Q.; Clark, K.L.; Guyton, R.A.; Vinten Johansen, J. 1999: AMP579, a new adenosine analog, inhibits neutrophil O2- generation, degranulation, adherence, and neutrophil-induced injury to coronary vascular endothelium by A2A receptor mechanism. Circulation 100(18): 1; 832

Baxter, G.F.; Ebrahim, Z.; Yelton, D.M. 2000: AMP579, an A1/A2A agonist, limits infarct size at reperfusion via a p42/p44 MAPK-dependent pathway. Circulation 102(18): 2; 212

Baxter, G.F.; Ebrahim, Z.; Yellon, D.M. 2001: AMP579, an adenosine A1 and A2A receptor agonist, attenuates lethal reperfusion injury in rat heart via the P42/P44 MAPK pathway. British Journal of Pharmacology 133(Proceedings Suppl): 7P

Baxter, G.F.; Kis, A.; Yellon, D.M. 2001: AMP579, an adenosine A1 and A2A receptor agonist, limits infarct size in rabbit heart in vivo when given at reperfusion Role of A2A receptor activation. British Journal of Pharmacology 133(Proceedings Suppl): 8P

Desmond, N.L.; Weinberg, R.J. 1999: AMPA and NMDA receptor protein at perforated and nonperforated spine synapses in hippocampal CA1. Society for Neuroscience Abstracts 25(1-2): 1485

Zhou, F.M.; Margolis, J.; Aroniadou Anderjaska, V.; Ennis, M.; Margolis, F.; Borrelli, E.; Shipley, M. 1999: AMPA and NMDA receptor-mediated synaptic transmission between olfactory nerve and juxtaglomerular cells and its presynaptic inhibition by dopamine D2 receptors in mice. Society for Neuroscience Abstracts 25(1-2): 1472

Nusser, Z. 2000: AMPA and NMDA receptors: similarities and differences in their synaptic distribution. Current Opinion in Neurobiology 10(3): 337-341

Hennou, S.; Diabira, D.; Louis, N.C.evassus Au; Ben Ari, Y.; Simon, H.; Gozlan, H. 1999: AMPA and NMDA receptors are functional before birth in the CA1 area of the rat intact hippocampus. Society for Neuroscience Abstracts 25(1-2): 1789

Dube, G.R.; Liu, G. 1999: AMPA and NMDA receptors display similar affinity during rapid synaptic-like glutamate applications. Society for Neuroscience Abstracts 25(1-2): 992

Smith, T.; Groom, A.; Turski, L. 1999: AMPA antagonists ameliorate experimental autoimmune encephalomyelitis. Society for Neuroscience Abstracts 25(1-2): 25

Morales-Alcelay, S.; Rubio, L.; Martinez, A. 2003: AMPA glutamate receptors and neuropathic pain. Mini Reviews in Medicinal Chemistry 3(7): 757-763

Brooks, J.W.; Rice, A.S.C.; Thompson, S.W.N.; Malcangio, M. 2002: AMPA inhibits electrically evoked calcitonin gene-related peptide release from the rat dorsal horn Reversal by cannabinoid antagonist SR141716A. British Journal of Pharmacology 136(Proceedings Suppl): 16P

Kawai, F.; Sterling, P. 1999: AMPA receptor activates a G protein that suppresses a cGMP-gated current in retinal ganglion cells. IOVS Investigative Ophthalmology and Visual Science 40(4): S816

Nikam, S.S.; Kornberg, B.E. 2001: AMPA receptor antagonists. Current Medicinal Chemistry 8(2): 155-170

Rutkauskaite, J.; Wagner, A.; Liljequist, S. 1999: AMPA receptor antagonists reduce ischemic brain damage identified by the novel, neuron-specific, fluorochrome Fluoro-Jade. Society for Neuroscience Abstracts 25(1-2): 577

Noga, J.T.; Hyde, T.M.; Bachus, S.E.; Herman, M.M.; Kleinman, J.E. 2001: AMPA receptor binding in the dorsolateral prefrontal cortex of schizophrenics and controls. Schizophrenia Research 48(2-3): 361-363

Monyer, H.; Fuchs, E.; Meyer, A.; Traub, R.; Doheny, H.; Faulkner, H.J.; Whittington, M.A. 2000: AMPA receptor diversity and regulation thereof in identified neurons. European Journal of Neuroscience 12(Suppl 11): 517

Osten, P.; Ziff, E.B. 1999: AMPA receptor forms a biochemically functional complex with NSF and alpha- and beta-SNAPs. Annals of the new York Academy of Sciences 868: 558-560

Treinies, I.; Sewing, S.; Raap, A.; Delaunois, A.; Depelchin, O.; Holst, J.J.; Gromada, J.; Mest, H.J.; Sher, E. 2003: AMPA receptor isoforms 2 and 3 mediate the stimulatory action of LY451646 on insulin and glucagon secretion in rats. Diabetologia 46(Suppl 2): A166

Strømgaard, K.; Mellor, I. 2004: AMPA receptor ligands: synthetic and pharmacological studies of polyamines and polyamine toxins. Medicinal Research Reviews 24(5): 589-620

Lapierre, L.; Valastro, B.; Gagne, J.; Ghribi, O.; Massicotte, G. 1999: AMPA receptor modulation by calcium in mouse brain sections Bidirectional control in the cortex and striatum formations. Society for Neuroscience Abstracts 25(1-2): 1737

Lynch, G. 2004: AMPA receptor modulators as cognitive enhancers. Current Opinion in Pharmacology 4(1): 4-11

Zarrinmayeh, H.; Zimmerman, D.M.; Ornstein, P.L.; Arnold, M.B.; Xi, X.L.; Skolnick, P. 2001: AMPA receptor potentiators as potentially novel antidepressants. Abstracts of Papers American Chemical Society 222(1-2): MEDI303

O'Neill, M.J.; Bleakman, D.; Zimmerman, D.M.; Nisenbaum, E.S. 2004: AMPA receptor potentiators for the treatment of CNS disorders. Current Drug Targets. Cns and Neurological Disorders 3(3): 181-194

Cornish, J.L.; Sun, A.B.; Kalivas, P.W. 1999: AMPA receptor stimulation in the nucleus accumbens reinstates cocaine-seeking behavior through a dopamine-independent mechanism. Society for Neuroscience Abstracts 25(1-2): 814

Lin, L.H.; Talman, W.T. 2000: AMPA receptor subunit GluR1 and neuronal nitric oxide synthase are colocalized in the nucleus tractus solitarii. FASEB Journal 14(4): A628

Carr, K.D.; Chau, L.S.; Cabeza de Vaca, S.; Gustafson, K.; Stouffer, M.; Tukey, D.S.; Restituito, S.; Ziff, E.B. 2010: AMPA receptor subunit GluR1 downstream of D-1 dopamine receptor stimulation in nucleus accumbens shell mediates increased drug reward magnitude in food-restricted rats. Neuroscience 165(4): 1074-1086

Fragioudaki, K.E.; Mitsacos, A.; Giompres, P.; Smith, A.; Triarhou, L.C.; Kouvelas, E.D. 2000: AMPA receptor subunit RNA transcripts in the cerebellum of normal and Purkinje cell degeneration mutant mice and in cerebellar grafts. European Journal of Neuroscience 12(Suppl 11): 40

Follett, P.L.; Talos, D.M.; Volpe, J.J.; Jensen, F.E. 2003: AMPA receptor subunit expression in human white matter during window of susceptibility to periventricular leukomalacia. Annals of Neurology 54(Suppl 7): S103

Kawahara, Y.kio; Kwak, Shin; Sun, Hui; Ito, Kyoko; Hashida, Hideji; Aizawa, Hitoshi; Kanazawa, Ichiro 2003: AMPA receptor subunit expression profile in spinal motoneurons of normal humans and ALS patients. Neuroscience Research Suppl (26): S52

Longone, P.; Spalloni, A.; Paolucci, E.; Prisco, S.; Mercuri, N.B.; Bernardi, G. 1999: AMPA receptor subunits expression in ALS-linked SOD1 mutant G93A. Society for Neuroscience Abstracts 25(1-2): 1834

Li, P.; Kerchner, G.A.; Sala, C.; Wei, F.; Huettner, J.E.; Sheng, M.; Zhuo, M. 1999: AMPA receptor-PDZ interactions and PKC mediate synaptic facilitation in spinal cord dorsal horn neurons. Society for Neuroscience Abstracts 25(1-2): 1238

Kelland, E.E.; Toms, N.J. 2001: AMPA receptor-mediated excitotoxic cell death in rat cultured oligodendrocyte progenitor cells. British Journal of Pharmacology 133(Proceedings Suppl): 139P

Bravo, S.O.; Henley, J.M.; Rodriguez Ithurralde, D. 2003: AMPA receptors are modulated by acetylcholinesterase. Molecular and Cellular Proteomics 2(9): 736

Rosa, M.L.N.M.; Guimaraes, F.S.; Pearson, R.C.A.; Del Bel, E.A. 2000: AMPA receptors flip isoforms mRNA expression are induced in hippocampus and entohinal cortex by stress. European Journal of Neuroscience 12(Suppl 11): 393

Turrigiano, G.G. 2000: AMPA receptors unbound: membrane cycling and synaptic plasticity. Neuron 26(1): 5-8

Beneyto, M.; Meador-Woodruff, J.H. 2003: AMPA- and NMDA-associated postsynaptic protein expression in the human dorsolateral prefrontal cortex. Annals of the new York Academy of Sciences 1003: 352-355

Lamsa, K.; Palva, M.; Kaila, K.; Taira, T. 1999: AMPA-R-mediated EPSCs in CA1 neurons evoked by synchronous gamma frequency bursts of CA3 region in the P0-P2 rat hippocampus. Society for Neuroscience Abstracts 25(1-2): 993

Kamboj, R.; Elliott, C.E.; Nutt, S.L. 2002: AMPA-binding human GLuR3 receptors. Official Gazette of the United States Patent and Trademark Office Patents 1260(1)

Kamboj, R.; Elliott, C.E.; Nutt, S.L. 2000: AMPA-binding human GluR2 receptors. Official Gazette of the United States Patent and Trademark Office Patents 1232(3)

Kamboj, R.; Elliott, C.E.; Nutt, S.L. 2002: AMPA-binding human gluR4 receptor methods. Official Gazette of the United States Patent and Trademark Office Patents 1256(3)

Jacoby, R.A.; Wu, S.M. 2000: AMPA-preferring receptors mediate excitatory inputs to primate ganglion cells. IOVS Investigative Ophthalmology and Visual Science 41(4): S938

Steinhaeuser, C.; Schroeder, W.; Hinterkeuser, S.; Seifert, G. 2001: AMPA-receptor mediated inhibition of inward rectifier K+ channels in immature astrocytes of mouse hippocampus. Pfluegers Archiv European Journal of Physiology 441(6 Suppl): R146

Qin, P.; Pourcho, R.G. 1999: AMPA-selective glutamate receptor subunits GluR2 and GluR4 Localization in the cat retina. IOVS Investigative Ophthalmology and Visual Science 40(4): S236

Kil, A.C.; Bar, P.R.; Shaw, P.J. 2000: AMPA-toxicity in cultured spinal cord slices of SOD1 transgenic mice. European Journal of Neuroscience 12(Suppl 11): 230

Aicher, S.A.; Kraus, J.A.; Patel, A.; Sharma, S. 1999: AMPA-type glutamate receptor density is increased in the nuclei of the solitary tract of spontaneously hypertensive rats. Society for Neuroscience Abstracts 25(1-2): 12

Satake, S.; Konishi, S. 2001: AMPA-type glutamate receptor inhibits cerebellar GABA-mediated transmission via G protein-coupled mechanisms. Zoological Science 18: 107

Krampfl, K.; Schlesinger, F.; Zoerner, A.; Dengler, R.; Bufler, J. 2001: AMPA-type glutamate receptors Contribution of posttranslational mRNA editing to kinetic properties. Pfluegers Archiv European Journal of Physiology 441(6 Suppl): R272

Smith, T.C.; Howe, J.R. 1999: AMPA-type glutamate receptors in migrating cerebellar granule cells. Society for Neuroscience Abstracts 25(1-2): 975

Ratte, S.; Collinge, J.; Jefferys, J.G.R. 2003: AMPA/KA receptor independent epileptiform bursts in the hippocampus of a mouse model of variant CJD. British Journal of Pharmacology 139(Proceedings Suppl): 3P

Satake, S.; Konishi, S. 1999: AMPA/kainate receptor-mediated presynaptic modulation at cerebellar GABAergic synapses. Zoological Science 16(Suppl ): 122

Norman, B.; Knutsson, A.; Sylven, C.; Andersson, B. 2002: AMPD1 gene polymorphism in heart failure patients determined by a new assay. FASEB Journal 16(5): A1129

Taubert, G.; Winkler, R.; Senges, J.; Hoffmann, M.; Maerz, W.; Winkelmann, B.R.; Klein, B.; Goek, R. 2001: AMPD1 gene polymorphism presents no differences in coronary artery disease severity and related complications compared to AMPD1 gene wild type in 3258 invasively investigated patients. European Heart Journal 22(Abstract Suppl): 162

Jobin, J.; Allaire, J.; Noel, M.; Leblanc, P.; Maltais, F. 2002: AMPD1 genotype frequency in patients with COPD. Medicine and Science in Sports and Exercise 34(5 Suppl): S179

Horman, S.; Beauloye, C.; Vertommen, D.; Vanoverscheide, J.L.; Hue, L.; Rider, M.H. 2003: AMPK activation during myocardial ischemia inhibits protein synthesis by increasing eukaryotic elongation factor-2 phosphorylation independently of the mTOR pathway. Circulation 108(17): IV296

Rubin, L.J.; Feng, X.; Magliola, L.; Jones, A.W. 2004: AMPK in Vascular Smooth Muscle Activation by Metabolic Challenge. FASEB Journal 18(4-5): Abstract 829

Hue, L. 2001: AMPK participates in the stimulation of heart glycolysis by ischemia. Journal of Molecular and Cellular Cardiology 33(6): A145

Thomson, D.M.; Gordon, S.E. 2004: AMPK phosphorylation during skeletal muscle overload in young and old rats. FASEB Journal 18(4-5): Abstract 237

Nagata, D.; Mogi, M.; Walsh, K. 2002: AMPK signaling in endothelial cells is essential for angiogenesis under hypoxic but not normoxic conditions. Circulation 106(19): II113

Andreelli, F.; Viollet, B.; Vaulont, S. 2003: AMPK, control of insulin secretion and resistance. M-S (Medecine Sciences) 19(5): 541-542

Sheffield Moore, M.; Yeckel, C.; Jiang, J.; Paddon Jones, D.; Wolfe, R.; Urban, R. 2003: AMPKalpha2 activity in response to moderate-intensity aerobic and resistance exercise in younger and older men. Diabetes 52(Suppl 1): A239

Tamatsukuri, S.; Yawata, H.; Sasaki, M.; Murata, T.; Sakakura, Y.; Hirose, T.; Nunes, J.A.; Pai, A.; Takeuchi, M.; Ohtake, K.; Nishioka, K. 2002: Amplinattm Mpx Hbv/Hcv/Hiv-1 System for Nationwide Blood Screening in Japan. Vox Sanguinis 83(Suppl 2): 114

Lorinczy, D.M.; Belagyi, J. 2000: AMPPNP produces global and local conformational changes in myosin. Biophysical Journal 78(1 Part 2): 235A

Vogel, J.S.; Clifford, A.J. 2004: AMS kinetic analysis of slowly cleared compartments implications for nutraceuticals. FASEB Journal 18(4-5): Abstract 405

Montorsi, F.; Carmgnani, G.; Campo, B.; Giammnusso, B.; Salonia, A.; Briganti, A.; Deho, F.; Rigatti, P. 2004: AMS three-piece inflatable implants for erectile dysfunction A long-term multi-institutional study in 300 consecutive patients. Journal of Urology 171(4 Suppl): 237

Stallmach, A.; Marth, T.; Wittig, B.M.; Neurath, M.; Zeitz, M.; Hombach, A.; Abken, H. 2002: AN IL-12 2-IgG-fusion protein ameliorates TNBS-colitis and inhibits human lymphocyte proliferation and IFN-gamma secretion. Gastroenterology 122(4 Suppl 1): A-391

Pasinetti, G.M.; Ho, L.; Pompl, P. 2002: AN1792 vaccination immunotherapy in Alzheimers disease The case of a therapy before its time. Neurobiology of Aging 23(5): 683-684

Stegmüller, J.; Schneider, S.; Hellwig, A.; Garwood, J.; Trotter, J. 2003: AN2, the mouse homologue of NG2, is a surface antigen on glial precursor cells implicated in control of cell migration. Journal of Neurocytology 31(6-7): 497-505

Lavaud, S.; Canivet, E.; Wuillai, A.; Mohajer, M.; Crost, T.; Renaux, J.L.; Chanard, J. 2001: AN69ST dialysis membrane allows reduced standard heparin doses during dialysis. Nephrology Dialysis Transplantation 16(6): A180

Tuaillon, E.; Borg, J.Y.; Levesque, H.; Jouen Beades, F.; Voiment, H.; Koutouzov, S.; Gilbert, D.; Tron, F. 2000: ANA are frequently observed in the primary anti-phospholipid syndrome and have different immunofluorescence staining patterns and antigenic specificities. Journal of Autoimmunity 15(2): A54

Hughes, R.G.; Karim, A.; Harden, E.L.; Bradwell, A.R. 2003: ANA patterns on ethanol-fixed neutrophils. Kidney and Blood Pressure Research 26(4): 271-272

Truchaud, A.; Delaroche, O. 2003: ANAES and GBEA combined requirements: application to POCT. Annales de Biologie Clinique 61(2): 159-163

Yang, J.; Alcorta, D.; Preston, G.; Munger, W.; Phillips, B.; Jennette, C.; Falk, R. 2000: ANCA IgG and F 2 fragments induce changes in leukocyte gene transcription. Clinical and Experimental Immunology 120(Suppl 1): 41

Jancova, E.; Rihova, Z.; Rychlik, I.; Tesar, V. 2003: ANCA Positive renal vasculitis in the Czech Registry of Renal Biopsies in years 1995-2001. Kidney and Blood Pressure Research 26(4): 251

Hewins, P.; Savage, C.O.S. 2003: ANCA and neutrophil biology. Kidney and Blood Pressure Research 26(4): 221-225

Labonia, W.D.; Arias, C. 2001: ANCA associated interstitial nephritis induced by drugs A case report. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 655A

Bernis, C.; Garcia, A.; Alegre, L.; Fernandez, A.; Cirugeda, A.; Sanchez Tomero, J.A.; Selgas, R. 2002: ANCA associated vasculitis with renal presentation Incidence and natural history. Nephrology Dialysis Transplantation 17(Abstracts Suppl 1): 98

Rajp, A.; Tse, W.Y.; Briggs, D.; Drayson, M.; Savage, C.O.; Adu, D. 2001: ANCA binding to monocytes activates complement. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 638A

Selga, D.; Segelmark, M.; Wieslander, J.; Hellmark, T. 2003: ANCA during active vasculitis recognizes the C-terminal part of PR3. Journal of the American Society of Nephrology 14(Abstracts Issue): 634A

Orth, T.; Neurath, M.; Schirmacher, P.; Galle, P.R.; Mayet, W.J. 2000: ANCA in a novel rat model of chronic fibrosing cholangitis induced by local administration of a hapten reagent into the dilated bile duct. Clinical and Experimental Immunology 120(Suppl 1): 45

Orth, T.; Neurath, M.F.; Schirmacher, P.; Galle, P.R.; Mayet, W.J. 1999: ANCA in a rat model of chronic cholangitis. Journal of Hepatology 30(Suppl 1): 72

Locht, H.; Skogh, T.; Wiik, A. 2000: ANCA in reactive arthritis, rheumatoid arthritis and ulcerative colitis. Clinical and Experimental Immunology 120(Suppl 1): 56

Smyth, C.L.; Pusey, C.D.; Haskard, D.O. 2002: ANCA induce leucocyte adhesion to endothelial cells mediated by E-selectin and integrins under conditions of flow. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 170A

Sediva, A.; Jethwa, H.S.; Bartunkova, J.; Falk, R.J.; Jennette, J.C.arles 2000: ANCA mediated inhibition of pseudomonadocidia in children with CF. Clinical and Experimental Immunology 120(Suppl 1): 54

Jancova, E.; Tesar, V.; Bartunkova, J.; Zabka, J.; Rychlik, I.; Merta, M.; Rysava, R.; Chabova, V.; Stejskalova, A. 1999: ANCA positive patients with renal failure - One centre experience. Blood Purification 17(4): 228

Bae, J.; Choi, H.K.; Niles, J.L. 1999: ANCA positive vasculitis presenting as idiopathic pulmonary fibrosis. Arthritis and Rheumatism 42(9 Suppl): S316

Pelclova, D.; Bartunkova, J.; Fenclova, Z.; Lebedova, J.; Hladikova, M.; Janu, P. 2003: ANCA positivity and occupational exposure to asbestos. Kidney and Blood Pressure Research 26(4): 252

Preston, G.A.; Falk, R.J. 2001: ANCA signaling: not just a matter of respiratory burst. Kidney International 59(5): 1981-1982

Tervaert, J.W.C. 2003: ANCA testing in monitoring the activity of the disease. Kidney and Blood Pressure Research 26(4): 226-230

Stone, J.H.; Talor, M.; Stebbing, J.; Rose, N.R.; Hellmann, D.B.; Burek, C.L.nne 1999: ANCA testing in patients suspected of ANCA-associated conditions Immunofluorescence and ELISA techniques in 916 consecutive patients. Arthritis and Rheumatism 42(9 Suppl): S316

Van Der Geld, Y.M.; Simpelaar, A.; Van Der Zee, R.; Terveart, J.W.C.hen; Stegeman, C.A.; Limburg, P.C.; Kallenberg, C.G.M. 2000: ANCA to proteinase 3 in Wegeners granulomatosis Epitope analysis using synthetic peptides. Clinical and Experimental Immunology 120(Suppl 1): 51

Hauer, H.A.; Bajema, I.M.; Van Houwelingen, J.C.; Noel, L.H.; Ferrario, F.; Waldherr, R.; Bruijn, J.A.; Hagen, E.C. 2001: ANCA-associated glomerulonephritis Differences between diagnostic and serologic subgroups. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 729A

Gibson, K.L.; Szuch, C.L.; Thomas, D.B.; Ferris, M.E.; Davis, L.R.; Gipson, D.S. 2001: ANCA-associated glomerulonephritis in children Patient and renal survival. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 101A

Duran, E.; Merkel, P.A.; Sweet, S.; Swan, N.; Babikian, V.L. 2004: ANCA-associated small vessel vasculitis presenting with ischemic optic neuropathy. Neurology 62(1): 152-153

Iking Konert, C.; Scherer, A.; Schneider, M. 2003: ANCA-associated systemic vasculitis with pulmonary manifestation. Zeitschrift fuer Rheumatologie 62(1): 82-83

Haubitz, M.; Groh, A.; Brunkhorst, R. 2000: ANCA-associated vasculitis and Chlamydia pneumoniae infection. Clinical and Experimental Immunology 120(Suppl 1): 49

Watts, R.; Gonzalez Gay, M.; Garcia Porrua, C.; Lane, S.; Bentham, G.; Scott, D. 2000: ANCA-associated vasculitis in two European regions. Clinical and Experimental Immunology 120(Suppl 1): 60

Kettritz, R.; Choi, M.; Butt, W.; Rane, M.; Rolle, S.; Luft, F.C.; Klein, J.B. 2001: ANCA-mediated activation of human neutrophils is controlled by phosphatidylinositol-3-kinase/Akt. Kidney and Blood Pressure Research 24(4-6): 366

Eisenberger, U.; Fakhouri, F.; Mahr, A.; Vanhille, P.; Beaufils, H.; Guillevin, L.; Lesavre, P.; Noel, L. 2003: ANCA-negative pauci-immune renal vasculitis A clinical and histopathological study of 20 cases. Kidney and Blood Pressure Research 26(4): 281

Moosig, F.; Csernok, E.; Kumanovic, G.; Gross, W.L.dwig 1999: ANCA-opsonisation of apoptotic neutrophils leads to release of proinflammatory mediators after ingestion by macrophages. Arthritis and Rheumatism 42(9 Suppl): S192

Jancova, E.; Tesar, V.; Bartunkova, J.; Zabka, J.; Rychlik, I.; Merta, M.; Rysava, R.; Chabova, V.; Stejskalova, A. 2000: ANCA-positive renal vasculitis One centre experience. Nephrology Dialysis Transplantation 15(9): A85

Greenfield, J.R.; McGrath, M.; Kossard, S.; Charlesworth, J.A.; Campbell, L.V. 2002: ANCA-positive vasculitis induced by thioridazine: confirmed by rechallenge. British Journal of Dermatology 147(6): 1265-1267

Nowack, R.; Grab, I.; Flores Suarez, L.F.; Yard, B.; Van Der Woude, F.J. 1999: ANCA-titers, even of IgG subclasses and soluble CD14 do not reflect disease-activity in patients with ANCA-associated vasculitis. Journal of the American Society of Nephrology 10(Program and Abstr. Issue): 517A

Mylonaki, Maria; Buckland, Matthew; Longhurst, Hilary; De Silva, Anupama D.; Ballinger, Anne; Rampton, David 2002: ANCA/ASCA profile in the prediction of clinical phenotype in Crohns disease. Gastroenterology 122(4 Suppl 1): A-179

Bhaskaran, M.; Reddy, K.; Kavuru, S.; Kapasi, A.A.; Singh, J.; Singhal, P.C. 2001: ANG II amplifies HIV-1 gp120-induced mesangial cell apoptosis and oxidative stress. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 798A

Ding, G.; Reddy, K.; Bhaskaran, M.; Singhal, P.C. 2000: ANG II promotes visceral glomerular epithelial cell apoptosis via TGF-beta, smad3, Fas/FasL and altered bcl-2/bax ratio. Journal of the American Society of Nephrology 11(Program and Abstract Issue): 419A

Reddy, K.; Ding, G.; Bhaskaran, M.; Kapasi, A.A.; Singhal, P.C. 2000: ANG II-induced proximal tubular cell apoptosis is mediated through TGF-beta, Fas, FasL, and altered ratio of bcl-2/bax. Journal of the American Society of Nephrology 11(Program and Abstract Issue): 463A

Chiu, T.K.; Dickerson, R.E. 2000: ANG crystal structures of B-DNA reveal sequence-specific binding and groove-specific bending of DNA by magnesium and calcium. Journal of Molecular Biology 301(4): 915-945, 25 August

Bauer, J.A.; Morrison, B.; Oates, R.; Lee, P.; Borden, E.; Lindner, D.J. 2003: ANGIOZYME and interferon-alpha2b synergistically inhibit tumor angiogenesis. Proceedings of the American Association for Cancer Research 44: 230

Hortobagyi, G.; Weng, D.; Elias, A.; Rugo, H.; Urba, W.; Margolin, K.; Radka, S.; Aitchison, R.; Parker, V.; Usman, N.; Capra, W.; Wolin, M.; Gilad, G. 2002: ANGIOZYME treatment of stage IV metastatic breast cancer patients Assessment of serum markers of angiogenesis. Breast Cancer Research and Treatment 76(Suppl 1): S97

Kramer, G.W. 2003: ANIML Analytical Information Markup Language for spectroscopy and chromatography data. Abstracts of Papers American Chemical Society 226(1-2): CINF 80

Bottner, S.; Kuhlmann, M.; Horvay, K.; Heinekamp, T.; Strathmann, A.; Droge Laser, W. 2003: ANK1 A regulator of pathogen-induced cell-death. Free Radical Research 37(Suppl 2): 17

William, M.; Garcia, A.; Hamilton, E.; Bundgaard, H.; Rasmussen, H. 2004: ANP activates the sarcolemmal sodium pump via nitric oxide synthase. Biophysical Journal 86(1): 227a

Barber, M.N.; Gaspari, T.A.; Dusting, G.J.; Woods, R.L. 2000: ANP and CNP preserve endothelium-dependent vasodilation, but only CNP prevents neointima formation, in experimental atherosclerosis. Journal of Submicroscopic Cytology and Pathology 32(3): 449

Schmitt, M.; Broadley, A.J.M.; Gunaruwan, P.; Taylor, J.S.W.; Lee, L.; Cockcroft, J.C.; Struthers, A.; Frenneaux, M.P. 2002: ANP but not CNP modifies forearm vascular tone in CHF. European Heart Journal 23(Abstract Suppl): 424

Tsukada, T.; Takei, Y. 2001: ANP decreases plasma Na+ concentration through its inhibitory actions on drinking and intestinal NaCl absorption. Zoological Science 18: 25

Maron, M.B.; Stader, S.M.; Folkesson, H.G. 2003: ANP does not cause the impaired beta-adrenoceptor-stimulated alveolar liquid clearance produced by prolonged isoproterenol infusion. FASEB Journal 17(4-5): Abstract

Lonardo, G.; Cerbai, E.; Giunti, G.; Bonacchi, M.; Casini, S.; Sani, G.; Mugelli, A. 2002: ANP positively modulates the hyperpolarization-activated current A possible link between stretch and arrhythmogenesis?. Circulation 106(19): II257

Foernges, A.C.; Kiemer, A.K.; Gerwig, T.; Gerbes, A.L.; Vollmar, A.M. 2003: ANP preconditioning attenuates RNA-binding activity of Iron-Regulatory Protein-1 during hepatic ischemia-reperfusion independent of HO-1 induction. Naunyn-Schmiedeberg's Archives of Pharmacology 367(Suppl 1): R106

Gerwig, T.; Meissner, H.; Arnholdt, H.; Bilzer, M.; Kiemer, A.K.; Vollmar, A.M.; Gerbes, A.L. 2001: ANP preconditioning protects against hepatic ischemia-reperfusion injury by attenuating necrotic and apoptotic cell death. Hepatology 34(4 Pt 2): 202A

Schmitt, M.; Nightingale, A.K.; Broadley, A.; Taylor, J.; Campbell, R.; Cockcroft, J.; Frenneaux, M.P. 2001: ANP regulates venous capacitance in man. Clinical Science (London) 101(2): 1P

Borges, A.; Sanchez De Villaroel, S.; De Becemberg, I.L.; Alfonzo, M.J.; Gonzalez De Alfonzo, R. 2000: ANP- and CNP-sensitive guanylyl cyclases are present in bovine airway smooth muscle. Biochemical Society Transactions 28(5): A265

Silberbach, M.; Gorenc, T.; Hershberger, R.E.; Steyger, P.S.; Roberts, C.T.Jr 1999: ANPs anti-hypertrophic action requires activation of MEK and ERK and is Raf independent in neonatal rat ventriculocytes. Pediatric Research 45(4 Part 2): 31A

Perronne, C.; Carrat, F.; Banisadr, F.; Morand, P.; Lunel, F.; Rosenthal, E.; Pol, S. 2002: ANRS HC02 - Ribavic A randomized controlled trial of pegylated-interferona-2b plus ribavirin vs interferona-2b plus ribavirin as primary treatment of chronic hepatitis C in HIV co-infected patients. Hepatology 36(4 Part 2): 283A

Schenk, A.; Roecker, C.; Lamb, D.C.; Nienhaus, G.U.rich 2000: ANS binding to apomyoglobin studied by time-gated fluorescence correlation spectroscopy. European Biophysics Journal 29(4-5): 266

Jankovic, N.; Varlaj Knobloch, V.; Pavlovic, D. 2001: ANS dysfunction and blood pressure regulation in CAPD patients. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 429A

Dehmel, J.C. 1999: ANSI/HPS N1353 TENORM Standard-Update of development activities. Health Physics 76(6 Suppl): S169

Chavany, C.; Martini, J.F.; Valle, R.P.C.; Jendoubi, M. 2002: ANTIBIOMIXTM Antibody-based target discovery and validation for cancer by matrix protein array. Proceedings of the American Association for Cancer Research 43: 455

Atwell, J.E.; Vinson, C.; Yuspa, S.H. 2001: AO-1 mediates apoptosis and altered epidermal differentiation in keratinocytes from PKCalpha transgenic mice. Proceedings of the American Association for Cancer Research 42: 422

Chojnowski, A.; Coleman, N. 1999: AO/ASIF unreamed femoral nail: a minimally invasive approach to its insertion. Injury 30(3): 226-230

Anonymous 2003: AOHC Session 2301 Current Research in Occupational and Environmental Medicine, Altanta, GA, USA, May 3-8, 2003. Journal of Occupational and Environmental Medicine 45(7): 771-775

Rosenberg, D.W.; Bolt, A.B. 2000: AOM induces K-ras activation in the tumor resistant AKR/J mouse colon. Proceedings of the American Association for Cancer Research 41: 104

Banerjee, S.; Bhattacharyya, N. 2002: AP endonuclease, PARP and XRCC1 proteins interact with a truncated DNA polymerase beta, a DNA repair protein. Environmental and Molecular Mutagenesis 39(Suppl 33): 15

Johansen, C.; Iversen, L.; Ryborg, A.; Kragballe, K. 2000: AP-1 DNA binding activity is significantly reduced in involved psoriatic skin In vitro and in vivo regulation of AP-1 DNA binding activity by 1alpha,25 2D3 and calcipotriol. Journal of Investigative Dermatology 115(3): 534

Luo, F.; Hu, Z.; Zhao, X.; Yin, L.; Ya, C. 2001: AP-1 activated by latent membrane protein 1 is involved in progression of nasopharyngeal carcinoma. Proceedings of the American Association for Cancer Research 42: 769

Eldred, A.K.; Durvasula, R.; Walz, G.; Cantley, L.G. 1999: AP-1 activation during treatment in chronic hemodialysis patients. Journal of the American Society of Nephrology 10(Program and Abstr. Issue): 71A

Daury, L.; Rodier, A.; Rochard, P.; Casas, F.; Busson, M.; Gamaleri, F.; Wrutniak Cabello, C.; Cabello, G. 2000: AP-1 activity is a crucial target of triiodothyronine involved in the stimulation of myoblast differentiation induced by the hormone. Endocrine Journal 47(Suppl August): 238

Kagami, S.; Urushihara, M.; Kondo, S.; Kitamura, M.; Koster, K.; Hisayama, T.; Kuroda, Y. 2000: AP-1 activity mediates alpha1beta1 integrin-dependent collagen matrix remodeling by rat mesangial cells. Journal of the American Society of Nephrology 11(Program and Abstract Issue): 531A

Mccabe, J.T.; Burrell, A.S. 1999: AP-1 and CREB protein DNA binding in rat supraoptic and paraventricular nuclei after acute and repeated osmotic stimulation. Society for Neuroscience Abstracts 25(1-2): 1693

Robinson, M.S.; Lui, W.W.Y.; Hirst, J. 2001: AP-1 and GGAs Two adaptors for TGN to endosome trafficking. Biochemical Society Transactions 29(3): A46

Lim, K.; Son, M.Y.; Seo, W.H.; Park, C.; Park, J.I.; Park, S.K.; Hwang, B.D. 2001: AP-1 and NF-kB are related to genistein-dependent induction of vimentin gene in HL-60 cells. European Journal of Cancer 37(Suppl 6): S130

Wang, J.; Khaletskiy, A.; Wong, J.Y.C.; Young, M.R.; Colburn, N.H.; Li, J.J.an 2000: AP-1 and NFKAPPAB are involved in radioresistance generation in human keratinocytes transformed by HPV18 E6/E7 and v-fos genes. Proceedings of the American Association for Cancer Research 41: 707

Kawachi, Y.; Roop, D. 2001: AP-1 and Sp1 cooperatively regulate differentiation-specific expression of the mouse loricrin gene via direct association. Journal of Investigative Dermatology 117(2): 523

Taimor, G.; Schneiders, D.; Best, P.; Piper, H.M. 2003: AP-1 and other transcription factors in apoptotic and hypertrophic cardiomyocytes. European Heart Journal 24(Abstract Suppl): 693

Krishna, N.S.; Edwards, J.; Underwood, M.A.; Grigor, K.M.; Bartlett, J.M.S. 2002: AP-1 as a mediator of androgen refractory prostate cancer. British Journal of Cancer 86(Suppl 1): S92

Chunhua, L.; Shen, Q.; Kim, H.; Denardo, D.; Wu, K.; Brown, P. 2003: AP-1 blockade inhibits breast cancer cell growth by preventing the recruitment of coactivators. Proceedings of the American Association for Cancer Research 44: 464

Shen, Q.; Lu, C.; Liu, Y.M.; Denardo, D.; Kim, H.T.; Brown, P.H. 2003: AP-1 blockade inhibits growth and suppresses G1 cyclin expression in breast cancer cells. Proceedings of the American Association for Cancer Research 44: 634

Liu, Y.; Zhang, Y.; Ludes Meyers, J.; Munoz Medellin, D.; Kim, H.T.; Ge, G.; Schiff, R.; Osborne, C.K.; Brown, P.H. 2001: AP-1 blockade suppresses the in vitro and in vivo growth of MCF-7 breast cancer cells. Proceedings of the American Association for Cancer Research 42: 128

Hafezi, F.; Grimm, C.; Weitzman, J.B.; Wenzel, A.; Yaniv, M.; Reme, C.E. 1999: AP-1 complexes containing JunD are not essential for light-induced photoreceptor degeneration. IOVS Investigative Ophthalmology and Visual Science 40(4): S226

Sadowska, B.; Barrucco, R.; Radhakrishnan, S.; Kim, J.; Khalili, K.; Safak, M. 2002: AP-1 family members, c-Jun and c-Fos, regulate transcription from JC virus promoters in glial cells. Journal of Neurovirology 8(Suppl 1): 107-108

Alfano, M.; Vicenzi, E.; Rizzi, C.; Tambussi, G.; Lazzarin, A.; Poli, G. 2002: AP-1 mediated-CXCL8 expression up-regulates HIV infection and virus replication. Journal of Interferon and Cytokine Research 22(Suppl 1): S-185

Bradbury, C.M.; Wei, S.J.; Locke, J.E.; Spitz, D.R.; Gius, D. 1999: AP-1 overexpression in H2O2-resistant cells contributes to resistance to thermal radiosensitization. Free Radical Biology and Medicine 27(Suppl 1): S59

Hornberg, J.J.; Langerak, P.; Dekker, H.; Lankelma, J. 2003: AP-1 plays a role in cell-cell contact-mediated inhibition of cell growth in NRK fibroblasts. Proceedings of the American Association for Cancer Research 44: 262-263

Dobretsova, A.; Kokorina, N.A.; Wight, P.A. 2001: AP-1 potentiates myelin proteolipid protein gene expression through protein-DNA interactions formed in the antisilencer region of intron 1. Journal of Neurochemistry 78(Suppl 1): 167

Hilfiker Kleiner, D.; Hilfiker, A.; Kaminski, K.; Wollert, K.; Castellazzi, M.; Drexler, H. 2002: AP-1 transcription factor JunD is a negative regulator of cardiomyocyte hypertrophy. Circulation 106(19): II141

Toone, W.M.; Jones, N. 1999: AP-1 transcription factors in yeast. Current Opinion in Genetics and Development 9(1): 55-61

Gerdes, M.J.; Frost, N.A.; Levy, M.R.; Moitra, J.; Glick, A.B.; Vinson, C.; Yuspa, S.H. 2004: AP-1 transcriptional activity determines keratinocyte lineage commitment during tumorigenesis. Journal of Investigative Dermatology 122(3): A22

Carter, A.B.; Tephly, L.A.; Hunninghake, G.W. 2001: AP-1-dependent gene expression in macrophages stimulated by phorbol esters requires an active p38 MAP kinase. FASEB Journal 15(4): A5

Kido, S.; Inoue, D.; Matsumoto, T. 2001: AP-1/interleukin -11 signaling cascades may be involved in PTH-induced bone formation ERK-dependent induction of delta-fosB and IL-11 by hPTH. Journal of Bone and Mineral Research 16(Suppl 1): S175

Proteau, G.A.; Wener, A.; Monge, J.C.rlos 2000: AP-2 activates an element in the 5untranslated region of the endothelin A receptor potentially regulating its developmental expression. Circulation 102(18): 2; 86

Van Laar, E.S.; Bar Eli, M.; Price, J.E. 1999: AP-2 expression reduces the metastatic potential of MDA-MB-231 breast cancer cells. Proceedings of the American Association for Cancer Research 40: 198

Ruiz, M.; Pettaway, C.; Song, R.; Troncoso, P.; Bar Eli, M. 2002: AP-2 transcription factor is a tumor suppressor gene in prostate cancer. Proceedings of the American Association for Cancer Research 43: 139

Ruiz, M.; Pettaway, C.; Troncoso, P.; Bar Eli, M. 2001: AP-2 transcription factor is associated with luminal differentiation in normal prostate epithelium and it is lost in prostate cancer. Proceedings of the American Association for Cancer Research 42: 625

Shaz, B.; Zhao, S.; Tahan, S. 2000: AP-2 transcription factor is upregulated in human in-situ and invasive malignant melanoma. Laboratory Investigation 80(3): 68A

West Mays, J.A.; Sivak, J.M.; Papagiotas, S.S.; Coyle, B.M.; Mohan, R.; Williams, T.; Fini, M.E. 2001: AP-2 transcription factors in the differentiating and regenerating corneal epithelium. IOVS Investigative Ophthalmology and Visual Science 42(4): S477

Coyle, B.M.; Papagiotas, S.S.; Choi, G.; Piatigorsky, J.; West Mays, J.A. 2001: AP-2alpha transcription factor controls cell migration in the developing lens. IOVS Investigative Ophthalmology and Visual Science 42(4): S922

Ahituv, N.; Erven, A.; Fuchs, H.; Balling, R.; De Angelis, M. Hrabe; Steel, K.P.; Avraham, K.B. 2001: AP-2alpha transcription factor mutation demonstrates the power of ENU. American Journal of Human Genetics 69(4 Suppl): 340

Sugita, M. 2003: AP-3-dependent immunity against microbial infection. Cell Structure and Function 28(4): 277

Piao, Z.; Malkhosyan, S. 2000: AP-PCR DNA fingerprinting of breast cancer. Proceedings of the American Association for Cancer Research 41: 277

Lukiw, W.J.; Mukherjee, P.K.; Dixon, D.; Prescott, S.M.; Leblanc, H.J.; Carver, L.A.; Bazan, N.N.G. 1999: AP1 and NF-kappaB levels in Alzheimers disease and age-matched association neocortex Relevance to neuroinflammatory processes and cyclooxygenase-2 transcription. Journal of Neurochemistry 72(Suppl ): S73

Saika, S.; Ohnishi, Y.; Ooshima, A.; Kao, W.W.Y. 2000: AP1 component expression in human ocular surface epithelia and in epithelial dysplasia before and after topical mitomycin C treatment. IOVS Investigative Ophthalmology and Visual Science 41(4): S259

Boord, J.B.; Fazio, S.; Uysal, K.; Babaev, V.R.; Brown, A.M.; Makowski, L.; Maeda, K.; Hotamisligil, G.S.; Linton, M.F. 2000: AP2 fatty acid binding protein expression by macrophages accelerates early atherosclerotic lesion formation in apo-E deficient mice. Circulation 102(18): 2; 230

Pietrzykowski, E. 2002: AP2-5B6 anti-HPV6b E5b. Hybridoma and Hybridomics 21(6): 509

Pietrzykowski, E. 2002: AP2-5G2 anti-HPV6b E7. Hybridoma and Hybridomics 21(6): 508

Senic Matuglia, F.; Goud, B.; Salamero, J. 2000: AP3-betaB A new interacting protein for Rab11 Their putative involvement in melanogenesis. Biology of the Cell 92(2): 172

Arvola, L.; Hassaf, D.; Ytrehus, K. 2001: AP5A and contractile function of guinea pig heart muscle. Journal of Molecular and Cellular Cardiology 33(6): A4

Van Ginneken, E.; Rongen, G.; Smits, P. 2000: AP5A-induced vasodilation is inhibited by theophylline in the human forearm vascular bed. Journal of Hypertension 18(Suppl 4): S215

Ramboyong, R.; Marinas, C.E.; Lim, A.; Flores, D.; Caguioa, E. 2001: APACHE II scores used as predictors of outcome in hypertensive patients with stroke admitted at ICU. European Journal of Neurology 8(Suppl 2): 41

Wang, X. 2002: APAF-1 an activator of caspase-3. Official Gazette of the United States Patent and Trademark Office Patents 1255(2)

Furukawa, Y.suke; Nishimura, Noriko; Kano, Yasuhiko; Nakamura, Mitsuru 2001: APAF-1 is a mediator of E2F-1-induced apoptosis in hematopoietic cells. Blood 98(11 Part 1): 758a-759a

Jada, S.R.; Stanslas, J.; Lajis, N.H.; Saad, S.; Hamzah, A.S.; Mccorroll, A.; Mathews, C.; Stevens, M.F.G. 2003: APAG-1 derivatives as antitumour agents. British Journal of Cancer 88(Suppl 1): S29

Cziepluch, C.; Bashir, T.; Lampel, S.; Lichter, P.; Grund, C.; Rommelaere, J. 2001: APAR-bodies Distinct autonomous parvovirus-induced nuclear structures. Biology of the Cell 93(3-4): 210

Niell, B.L.; Rennert, G.; Tomsho, L.P.; Bonner, J.D.; Gruber, S.B. 2002: APC D1822V and the risk of colorectal cancer. American Journal of Human Genetics 71(4 Suppl): 246

Petersen, G.M.; Hahnloser, D.; Rabe, K.; Snow, K.; Boardman, L.; Lindor, N.M.; Koch, B.; Wang, L.; Thibodeau, S.N. 2001: APC E1317Q variant is not associated with increased colorectal neoplasia risk. American Journal of Human Genetics 69(4 Suppl): 274

Bienz, M. 1999: APC: the plot thickens. Current Opinion in Genetics and Development 9(5): 595-603

Garza, K.M.; Chan, S.; Suri, R.; Schoenberger, S.; Ohashi, P.S. 2000: APC activation through CD40 breaks tolerance and induces autoimmunity. Journal of Investigative Dermatology 114(1): 215

Iwamoto, M.; Maltzman, T.; Ahnen, D.J. 1999: APC and beta-catenin expression in normal and neoplastic colonic mucosa. Gastroenterology 116(4 Part 2): A427

Akiyama, Y.; Nagasaki, H.; Nomizu, T.; Yuasa, Y. 2000: APC and beta-catenin gene mutations in colorectal adenomas from HNPCC patients. Proceedings of the American Association for Cancer Research 41: 595

Iwamoto, M.; Giardiello, F.M.; Boland, C.R.; Romans, K.; Chauhan, D.P.; Ahnen, D.J. 2001: APC and beta-catenin protein expression in adenomas of patients with familial polyposis. Gastroenterology 120(5 Suppl 1): A 294

Maltzman, T.; Iwamoto, M.; Franklin, W.; Stephens, J.; Ahnen, D. 1999: APC and beta-catenin staining in AOM-induced mouse colon tumors. Proceedings of the American Association for Cancer Research 40: 697

Silye, R.; Webersinke, G.; Heuritsch, S. 1999: APC and c-neu in malignant and benign melanocytic lesions. Virchows Archiv 435(3): 314

Bertagnolli, M.M. 1999: APC and instestinal carcinogenesis insights from animal models. Bradlow, H Leon Author, Fishman, Jack Author, Osborne, Michael P Author Annals of the New York Academy of Sciences; Cancer prevention: Novel nutrient and pharmaceutical developments 32-44

Yang, V.W. 2002: APC as a checkpoint gene: the beginning or the end?. Gastroenterology 123(3): 935-939

Gerstein, A.V.; Zhao, G.; Almeida, T.A.; Chess, E.; Papadopoulos, N. 2000: APC beta-catenin pathway mutations in cancers of the prostate. Proceedings of the American Association for Cancer Research 41: 872

Sanchez, M.; Meier, C.; Garcia, M.; Kaye, P. 1999: APC function of granuloma derived macrophages. Immunology 98(Suppl 1): 52

Lee, J.H.; Abraham, S.C.; Nam, J.H.; Choi, C.; Lee, M.C.; Park, C.S.; Juhng, S.W.; Rashid, A.; Hamilton, S.R.; Wu, T.T. 2002: APC gene mutations in gastric adenomas and flat dysplasias protect against progression. Laboratory Investigation 82(1): 135A-136A

Womack, L.; Lee, L.A.; Hylind, L.M.; Giardiello, F.M. 2000: APC germline mutations result in increased c-MYC expression in the flat mucosa of FAP patients. Gastroenterology 118(4 Suppl 2 Pt 1): A43

Louis, T.H.; Reed, B. 2003: APC localization linked to myosin VI movement through interaction with GLUT1CBP. Abstracts of Papers American Chemical Society 225(1-2): CHED 839

Laken, S.; Gruber, S.; Petersen, G.; Kinzler, K.; Vogelstein, B. 1999: APC mutation associated with familial colorectal cancer in ashkenazi jews. Official Gazette of the United States Patent and Trademark Office Patents 1220(2): 1495

Peters, J.A.; Lotze, M.T.; Sproul, L.; Pratt, V.; Rubinstein, W.S. 1999: APC mutation in woman with multiple desmoids A new syndrome or FAP variation?. American Journal of Human Genetics 65(4): A315

Meuller, J.; Engwall, Y.; Bergman, A.; Wahlstrom, J.; Bjork, J.; Nordling, M. 2001: APC mutations in Swedish FAP patients Preliminary results. American Journal of Human Genetics 69(4 Suppl): 252

Kim, J.C.; Roh, S.A.; Yu, C.S.; Kim, K.M.; Yang, S.K.; Kang, K.H.; Beck, N.E.; Bodmer, W.F. 1999: APC mutations in the hamartomatous and hyperplastic polyps of the colon. Proceedings of the American Association for Cancer Research 40: 274

Aust, D.E.; Terdiman, J.P.; Willenbucher, R.F.; Chang, C.G.; Baretton, G.B.; Waldman, F.M.; Loehrs, U. 2000: APC mutations in ulcerative colitis-related and sporadic colorectal cancers. Pathology Research and Practice 196(6): 409

Arnold, C.N.; Goel, A.; Compton, C.; Niedzwiecki, D.; Wasserman, L.; Mayer, R.J.; Bertagnolli, M.M.; Boland, C.R.chard 2002: APC promoter hypermethylation contributes strongly to loss of APC expression in colorectal cancers with allelic loss at 5q A study of CALGB 9865. Gastroenterology 122(4 Suppl 1): A-121

Palacios, J.; Esteller, M.; Matias Guiu, X.; Catasus, L.; Guo, M.; Moreno Bueno, G.; Hardisson, D.; Herman, J.G.; Prat, J. 2002: APC promoter hypermethylation in endometrial carcinomas. Laboratory Investigation 82(1): 205A

Mimori Kiyosue, Y.ko; Tsukita, Shoichiro 2001: APC protein is recruited to the cell cortex through its COOH-terminal PDZ-binding domain. Molecular Biology of the Cell 12(Suppl): 308a-309a

Van Der Neut Kolfschoten, M.; Dirven, R.J.; Tans, G.; Rosing, J.; Vos, H.L.; Bertina, R.M. 2000: APC resistance and mutations in the APC cleavage sites of factor V. Haemostasis 30(Suppl 1): 27-28

Schneider, D.M.; Heilmann, L.; V. Tempelhoff, G.F.; Niemann, F.; Knirsch, K. 1999: APC resistence and ProC Global in mothers and newborn cord blood at delivery. Annals of Hematology 78(Suppl 1): A87

Javid, S.H.; Hunt, D.H.; Moran, A.E.; Mueller, J.D.; Carothers, A.M.; Bertagnolli, M.M. 2003: APC truncation alters cytoskeletal function in the Min/+ mouse model of colorectal cancer. Proceedings of the American Association for Cancer Research 44: 287

Hughes, S.A.; Hunt, D.H.; Moran, A.E.; Mueller, J.D.; Carothers, A.M.; Bertagnolli, M.M. 2002: APC truncation alters cytoskeletal structure and microtubule stability in early intestinal tumorigenesis. Gastroenterology 123(1 Suppl): 7

Kapitanovic, S.; Cacev, T.; Radosevic, S.; Spaventi, R.; Pavelic, K. 2002: APC tumor suppressor gene in sporadic colon cancer. European Journal of Cancer 38(Suppl 1): S51

Liu, Z.; Hsu, H.; Xie, J.; Yang, P.; David, C.S.; Xu, X.; Mountz, J.; Zhang, H.G. 2002: APC-AdFasL treatment leads to clonal deletion of CII specific T cells and prevents CII induced arthritis in DQ8 transgene mice. FASEB Journal 16(5): A1045

Daly, C.; Dube, C.; Rollins, B.J. 2004: APC-Derived Monocyte Chemoattractant Protein-1 Provides Costimulatory Activity for CD4 Cells. FASEB Journal 18(4-5): Abstract 336

Grabbe, S.; Varga, G.; Gunzer, M. 2003: APC-T cell interactions during antigen presentation Relevance of beta2 integrins and differences between APC types. Journal of Investigative Dermatology 121(5): 1234

Meuller, J.; Bjork, J.; Engwall, Y.; Gronberg, H.; Holmberg, E.; Nordling, M. 2001: APC-gene mosaicism in sporadic attenuated FAP. European Journal of Human Genetics 9(Suppl 1): P0046

Rockwell, J.K.; Renshaw, M.; Katz, J.; Sambhara, S. 2002: APC/T cell contact kinetics and antigen threshold requirements for influenza nucleoprotein-specific CD8+ T cell clonal expansion. FASEB Journal 16(4): A718

Yamanaka, H.; Kondo, E.; Noguchi, K.; Koyama, K.; Nakagawa, H.; Nakamura, Y. 2000: APCL mRNA expression during mouse development. Neuroscience Research Suppl (24): S130

Ghio, Luciana; Boccola, Salvatore; Edefonti, Alberto; Vrech, Simone; Adami, Daniele; Garavaglia, Rosanna; De Chiara, Benedetta; Paglialonga, Fabio; Ardissino, Gianluigi 2002: APD patients management with the use of a new telecommunication system. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 395A

Kent, T.A.; Edwards, M.; Izumi, T.; Mitra, S.; Perez Polo, J.R.gino 1999: APE/Ref-1 DNA repair enzyme following middle cerebral artery occlusion/reperfusion. Stroke 30(1): 247

Metspalu, A.; Tonisson, N.; Zernant, J.; Lushnikov, A.; Kask, I.; Kurg, A. 2000: APEX chip for p53. European Journal of Human Genetics 8(Suppl 1): 144

Kepp, K.; Remm, M.; Lohmussaar, E.; Gerst Talas, U. 2002: APEX scaling up Optimisation of the high throughput Arrayed Primer Extension based DNA variation analysis for accurate and affordable large-scale projects. European Journal of Human Genetics 10(Suppl 1): 297

Pereira, C.ân.F.; Paridaen, J.T.M.L.; van de Bovenkamp, M.; Middel, J.; Verhoef, J.; Nottet, H.S.L.M. 2003: APHS can act synergically with clinically available HIV-1 reverse transcriptase and protease inhibitors and is active against several drug-resistant HIV-1 strains in vitro. Journal of Antimicrobial ChemoTherapy 51(5): 1181-1189

Sugiyama, T.; Asaka, M.; Nakamura, T.; Nakamura, S.; Yonezumi, S.; Seto, M. 2001: API2-MALT1 chimeric transcript is a predictive marker for the responsiveness of H. pylori eradication treatment in low-grade gastric MALT lymphoma. Gastroenterology 120(7): 1884-1885

Sagaert, Xavier; De Wolf Peeters, Christiane; Marynen, Peter; Baens, Matthys 2003: API2-MLT transgenic mice A model for the pathogenesis of MALT lymphomas?. Blood 102(11): 586a

Duncan, S.L. 2000: APIC State-of-the-Art Report: the implications of service animals in health care settings. American Journal of Infection Control 28(2): 170-180

Zabransky, R.J. 2001: APIC defines home health care infection criteria. Clinical Microbiology Newsletter 23(8): 64

Suzuki, A. 2000: APKC-PAR system mediates formation of polarized junctional structures and cell epithelialization. Cell Structure and Function 25(6): 372

Pierangeli, S.S.; Liu, X.; Espinola, R.G.; Harris, E.N. 2002: APL affects protein C activation in vivo. Lupus 11(9): 584

Levine, S.R.; Brey, R.L.; Tilley, B.C.; Thompson, J.L.T.; Sacco, R.L.; Costigan, T.M.; Rhine, C.; Murphy, A.; Levin, B.; Sciacca, R.R.; Triplett, D.A.; Mohr, J.P.; Apass Study Group 2002: APL and Stroke Study. Lupus 11(9): 559

Dawood, F.; Farquharson, R.G.; Quenby, S. 2002: APL and acquired activated protein C resistance Risk factors for fetal loss. Lupus 11(9): 562

Colorio, C.; Forastiero, R.; Martinuzzo, M.; Macchia, A.; Pombo, G.; Puente, D.; Rossi, A.; Carreras, L. 2002: APL and heparin induced thrombocytopenia type II in chronic thromboembolic pulmonary hypertension. Lupus 11(9): 593

Rai, R. 2002: APL and pregnancy loss Beyond thrombosis. Lupus 11(9): 563

Mcintyre, J.A.; Wagenknecht, D.R. 2002: APL and renal transplantation A risk assessment. Lupus 11(9): 546

Brey, R.L.; Levine, S.R. 2002: APL and the brain Treatment. Lupus 11(9): 559

Victoria, E.J.; Marquis, D.M.; Jones, D.S.; Yu, L. 2002: APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies. Official Gazette of the United States Patent and Trademark Office Patents 1259(4)

Toubi, E.; Kessel, A.; Hallas, K.; Zuckerman, E. 2002: APL in patients suffering from autoimmune hepatitis and primary biliary cirrhosis. Lupus 11(9): 623

Pierangeli, S.S.; Blank, M.; Espinola, R.G.; Shoenfeld, Y.; Harris, E.N.; Gharavi, A. 2002: APL induced by immunization with the phospholipid-binding site of B2glycoprotein I recognize conformational epitopes on a bacterial peptide. Lupus 11(9): 610

Mak, I.Y.H.; Rai, R.; Brosens, J.J.; Christian, M.; Hills, F.A.; Chamley, L.; Regan, L.; White, J.O. 2002: APL inhibition of human endometrial stromal cell differentiation in vitro. Lupus 11(9): 563

Raschi, E.; Testoni, C.; Corsini, E.; Khamashta, M.A.; Tincani, A.; Balestrieri, G.; Salmaggi, A.; Hess, D.; Meroni, P.L. 2000: APL reactivity with human brain microvascular endothelial cells. Journal of Autoimmunity 15(2): A26

Mandal, A.; Klotz, K.; Wolkowicz, M.J.; Shetty, J.; Jayes, F.L.; Flickinger, C.J.; Herr, J.C. 2000: APL17 and APLX Two novel human acrosomal pseudo-lysozymes. Molecular Biology of the Cell 11(Suppl): 520a-521a

Pierangeli, S.S.; Hall, J.L.; Espinola, R.G.; Ferrara, D.E.; Roye Green, K.; Harris, E.N. 2002: APLs activate nuclear factor kappa B on endothelial cells. Lupus 11(9): 589

Kim, H.; Conti Kelly, A.M.; Greco, T. 2002: APLs and recurrent coronary events after angioplasty. Lupus 11(9): 567

Bougueleret, L.; Bihain, B.; Denison, B.; Yen Potin, F. 2003: APM1 biallelic markers and uses thereof. Official Gazette of the United States Patent and Trademark Office Patents 1271(4)

Kinyoun, J.L. 2000: APMPPE associated with Wegener's granulomatosis. Retina 20(4): 419-420

Lanza Jacoby, S.; Miller, S. 1999: APO E-/- mice have increased mortality after endotoxin challenge. FASEB Journal 13(5 Part 2): A840

Javadi, E.; Doosti, M.; Rashtchizadeh, N.; Mohaghaghi, A.; Mahmoodi, M. 2001: APO isoforms and LP concentration in predict risk for coronary artery disease, a study in men 55 years of age. Clinical Chemistry and Laboratory Medicine 39(Special Suppl): S296

Buzello, M.; Schumm, K.; Toernig, J.; Faulhaber, J.; Ehmke, H.; Ritz, E.; Amann, K. 2002: APO knockout mice A new model to study the pathogenesis of cardiovascular changes in chronic renal failure. Pathology Research and Practice 198(3): 145-146

Trieb, K.; Cetin, E. 2003: APO-1 and Caspase-8 are distinct expressed in the human growth plate. Calcified Tissue International 72(4): 434

Valle, M.; Gascon, F.; Martos, R.; Ruz, F.J.; Rios, R.; Canete, R. 2001: APO-AI decrease and triglycerides increase serum levels in hyperinsulinemic obese children. Clinical Chemistry and Laboratory Medicine 39(Special Suppl): S247

Goldstein, L.B.; Vitek, M.P.; Dawson, H.; Bullman, S. 1999: APO-E genotype does not affect motor recovery after motor cortex injury in the mouse. Society for Neuroscience Abstracts 25(1-2): 822

Bishop, K.N.; Holmes, R.K.; Sheehy, A.M.; Malim, M.H. 2004: APOBEC-mediated editing of viral RNA. Science 305(5684): 645

Corbo, R.M.; Gambina, G.; Ruggeri, M.; Ferrari, G.; Scacchi, R. 1999: APOE -491 A/T polymorphism Lack of association with Alzheimers disease and relationships with apoE plasma levels. European Journal of Human Genetics 7(Suppl 1): 141

Martin, G.M. 1999: APOE alleles and lipophylic pathogens. Neurobiology of Aging 20(4): 441-443

Lovestone, S. 2000: APOE and Alzheimers disease Is tau the link?. Biochemical Society Transactions 28(1): A16

Singh, P.; Singh, M.; Mastana, S.S. 2003: APOE distribution in world populations with new data from the Indian and the British populations. American Journal of Human Genetics 73(5): 381

Singh, P.P.; Singh, M.; Gill, P.S.; Mastana, S.S. 2003: APOE distribution in world populations with new data from the Indian sub-continent and the British populations. American Journal of Physical Anthropology Suppl (36): 192

Diaz Arrastia, R.; Fair, S.; Gong, Y.; Agostini, M.A. 2002: APOE epsilon4 allele increases risk of late posttraumatic seizures. Epilepsia 43(Suppl 7): 275

Aerssens, J.; Raeymaekers, P.; Lilienfeld, S.; Parys, W. 1999: APOE genotype and response to galantamine treatment in Alzheimers disease. American Journal of Human Genetics 65(4): A195

Evans, R.M.; Hui, S.; Murrell, J.; Gao, S.; Lane, K.A.; Hall, K.S.; Hendrie, H.C. 2001: APOE genotype and risk for AD in a population-based study of African Americans Prevalence and incidence data. Neurology 56(8 Suppl 3): A112-A113

Grocott, H.P.; Laskowitz, D.T.; El Moalem, H.; Bainbridge, D.; Butler, A.M.; Newman, M.F. 2001: APOE genotype differentially influences the pro and anti-inflammatory response to cardiopulmonary bypass. Anesthesia and Analgesia 92(4 Suppl): SCA18

Frank, A.; Díez-Tejedor, E.; Bullido, M.J.; Valdivieso, F.; Barreiro, P. 2002: APOE genotype in cerebrovascular disease and vascular dementia. Journal of the Neurological Sciences 203-204: 173-176

Chapman, J.; Vinokurov, S.; Achiron, A.; Karussis, D.M.; Mitosek Szewczyk, K.; Birnbaum, M.; Michaelson, D.M.; Korczyn, A.D. 2000: APOE genotype is a predictor of long-term progression of disability in patients with multiple sclerosis. Neurology 54(7 Supp 3): A348-A349

Song, Y.; Liu, S. 2003: APOE genotypes and risk of coronary heart disease A meta-analysis of population studies. Circulation 108(17): IV726

Perez Tur, J.; Crook, R.; Hardy, J.; Borgaonkar, D.S. 1999: APOE haplotype segregating with late-onset familial Alzheimers disease for 200 years. American Journal of Human Genetics 65(4): A484

Akanji, A.O.; Fatania, H.; Al Radwan, R.; Al Shammri, S. 2003: APOE polymorphism and lipoprotein levels in a Gulf Arab population. Clinical Chemistry 49(S6): A162

Araki, S.I.; Koya, D.; Makiishi, T.; Kashiwagi, A.; Haneda, M. 2003: APOE polymorphism and the progression of diabetic nephropathy in Japanese subjects with type 2 diabetes mellitus Result of the prospective observational follow-up Study. Diabetes 52(Suppl 1): A183

Nicodemus, K.K.; Allen, C.; Roses, A.D.; Saunders, A.M.; Small, G.; Schmechel, D.; Conneally, P.M.; Haines, J.L.; Gilbert, J.G.; Vance, J.M.; Pericak Vance, M.A. 2002: APOE promoter region SNPs, APOE genotype, and risk of Alzheimer disease in cases, controls, and families. American Journal of Human Genetics 71(4 Suppl): 471

Li, Y.J.; Pericak Vance, M.A.; Haines, J.L.; Siddique, N.; Mckenna Yasek, D.; Martin, E.R.; Hung, W.Y.; Sapp, P.; Allen, C.I.; Chen, W.; Hosler, B.; Saunders, A.M.; Dellefave, L.; Brown, R.H.Jr.; Siddique, T. 2002: APOE promoter region is associated with age at onset of amyotrophic lateral sclerosis. American Journal of Human Genetics 71(4 Suppl): 450

Rebeck, G.W.; Growdon, W.B.; Deng, A.; Cheung, B.S.; Greenberg, S.M.; Hyman, B.T. 1999: APOE promoter/enhancer polymorphisms and APOE allele expression are independent of Alzheimer disease status. Society for Neuroscience Abstracts 25(1-2): 1058

Smart, M.C.; Dedoussis, G.; Louizou, E.; Yannakoulia, M.; Drenos, F.; Papoutsakis, C.; Maniatis, N.; Humphries, S.E.; Talmud, P.J. 2010: APOE, CETP and LPL genes show strong association with lipid levels in Greek children. Nutrition Metabolism and Cardiovascular Diseases: Nmcd 20(1): 26-33

Arciniegas, D.B.; Topkoff, J.L.; Filley, C.M.; Adler, L.E.; Ricketts, K.A.; Spector, E.B. 2002: APOE-epsilon4 in association with persistant neurocognitive impairment after traumatic brain injury. American Journal of Human Genetics 71(4 Suppl): 469

Croucher, P.I.; Shipman, C.M.; Perry, M.; Russell, G.G.; Camp, B.V.; Niesor, E.J.; Bentzen, C.L.; Vanderkerken, K. 2002: APOMINETM, a Novel Inhibitor of the Mevalonate/Isoprenoid Pathway, Promotes Apoptosis of Myeloma Cells In Vitro and Is Associated with a Modulation of the Myeloma Disease In Vivo. Blood 100(11): Abstract No. 3209

Mcphie, D.L.; Hines Peralta, A.U.; Pratt, K.G.; Neve, R.L. 1999: APP and PAK3 interact to mediate apoptosis in neurons. Society for Neuroscience Abstracts 25(1-2): 2127

Confaloni, A.M.; Crestini, A.; Campeggi, L.M.; Calamandrei, G.; Ricceri, L. 2000: APP and presenilin expression in cortex and hippocampus of rats after neonatally-induced cortical cholinergic hypoactivity. European Journal of Neuroscience 12(Suppl 11): 213

Davies, P.; Debernardis, J.; Espinoza, M.; Stahl, M.; Vianna, C. 2000: APP and tau phosphorylation in Alzheimers disease. Brain Pathology 10(4): 493

Fernandez, H.L.; Chen, M. 1999: APP normal processing is regulated by Ca2+ signaling. Society for Neuroscience Abstracts 25(1-2): 596

Zhang, J.; Watson, D.; Selkoe, D.J. 1999: APP sequence requirements for gamma-secretase recognition and cleavage. Society for Neuroscience Abstracts 25(1-2): 597

Franklin, S.R.; Goodwin, A.; Oostveen, J.; Buhl, A.; Mcarthur, R.A. 2000: APP-overexpressing transgenic mice are not impaired in acquisition of an olfactory discrimination. Journal of Psychopharmacology 14(3 Suppl): A52

Pradier, L.; Czech, C. 1999: APP/presenilin interaction Mapping and modelization in vitro. Society for Neuroscience Abstracts 25(1-2): 1300

Czech, C.; Dreisler, S.; Reboul, S.; Pradier, L. 1999: APP/presenilin interaction The amino-terminus of presenilin 2 is able to interact with Abeta42 in vitro. Society for Neuroscience Abstracts 25(1-2): 1600

Hardy, J.A.; Chartier Harlin, M C.; Goate, A.M.; Owen, M.J.; Mullan, M.J. 1999: APP70 mutant in Alzheimers disease. Official Gazette of the United States Patent and Trademark Office Patents 1220(1): 492

Bonci, Desiree; Felli, Nadia; Hahne, Michael; Peschle, Cesare; De Maria, Ruggero 2003: APRIL is an autocrine growth factor for megakaryocytes. Blood 102(11): 140b

Gaillard, C.; Pethe, C.; Moffatt, B.; Laloue, M. 1999: APRT deficiency in Arabidopsis thaliana results from a mutation in the gene APT1. Biologia Plantarum 42(Suppl ): S117

Belloni, F.L.; Lowy, M.; Matyas, M.L. 2003: APS Archives of Teaching Resources a collegial sharing resource for physiology teachers. FASEB Journal 17(4-5): Abstract

Baleva, M.P.; Nikolov, K.V. 2002: APS The effect of the pendulum. Lupus 11(9): 595

Harris, E.N.; Pierangeli, S.; Gharavi, A. 2002: APS Unsolved mysteries. Lupus 11(9): 571

Ziporen, L.; Levi, Y.; Rauova, L.; Shoenfeld, Y. 1999: APS and HIT Is there crossreactive epitopes and common mechanisms?. Journal of Autoimmunity (Suppl ): 88

Macejova, Z.; Szilasiova, J.; Trejbal, D. 2002: APS and its clinical manifestations. Lupus 11(9): 593

Latino, J.O.; Bierfass, G.R.; Carballo, O.G.; Fernandez Romero, D.S.; Paolini, M.V.; Prada, M.E.; Scher, U.; Pesaresi, M.; Di Lonardo, A.M. 2002: APS and pregnancy A retrospective study. Lupus 11(9): 614

Maina, A.; Donvito, V.; Balbi, L. 2002: APS and pregnancy A seven year experience. Lupus 11(9): 611

Cathebras, Pascal; Roy, Michel; Baccot, Sylvianne; De Filippis, Jean Pierre 2000: APS and/or HELLP syndrome Thrombotic microangiopathy with liver, gut, and bone infarction during pregnancy. Journal of Autoimmunity 15(2): A67

Falcini, F.; Cimaz, R.; Avcin, T. 2002: APS can occur in children, too Proposal for guidelines in the pediatric age. Lupus 11(9): 557

Katzav, A.; Pick, C.G.; Korczyn, A.D.; Blank, M.; Shoenfeld, Y.; Chapman, J. 2002: APS exacerbates cognitive impairment in an APP mouse model of Alzheimers disease. Lupus 11(9): 604

Hadacova, I.; Vavrincova, P.; Hladikova, E.; Sukova, M.; Vavrinec, J. 2002: APS in children with systemic autoimmune disease. Lupus 11(9): 555

Kljukvina, N.G.; Shekshina, S.V.; Baranov, A.A.; Nassonov, E.L. 2002: APS in male lupus. Lupus 11(9): 631

Farquharson, R.G.; Quenby, S.M.; Greaves, M. 2002: APS in pregnancy A controlled treatment trial. Lupus 11(9): 580

Levy, R.A.; Jesus, N.R.; Almeida, M.V.L.; Albuquerque, E.M.N.; Trajano, A. 2001: APS in pregnancy Favorable outcome with coumadin treatment from week 14 to 36. Lupus 10(Suppl 1): S89

Mccarty, G.A.; Cason, T.E.; Scully, K.W. 2002: APS in the UVA clinical data repository 1996-2001. Lupus 11(9): 609

Ugalde, J.; Egurbide, V.; Ruiz Irastorza, G.; Aguirre, C. 2002: APS is a major cause of chronic damage in patients with SLE. Lupus 11(9): 595

Daugas, E.; Nochy, D.; Caudwell, V.; Jacquot, C. 2002: APS nephropathy in patients with isolated antiphospholipid antibodies. Lupus 11(9): 622

Vacca, A.; Littera, R.; Carta, M.; Piras, E.; Oppi, S.; Arras, M.; Marongiu, F.; Parodo, G.; La Nasa, G.; Faa, G.; Contu, L. 2000: APS syndrome in a patient with non-Hodgkin lymphoma of the marginal zone Effectiveness of chemoimmunotherapy with Fludarabina and Rituximab. Journal of Autoimmunity 15(2): A50

Cherniack, A.D.; Coulter, S.M.; Bose, A.; Karkut, C.J.; Czech, M.P. 1999: APS, a novel insulin receptor substrate and binding partner highly expressed in muscle and fat. Diabetes 48(Suppl 1): A326

Perheentupa, J. 2002: APS-I/APECED: the clinical disease and therapy. Endocrinology and Metabolism Clinics of North America 31(2): 295-320 Vi

She, Jin Xiong 1999: APS1 The monogenic autoimmunity of aire. Journal of Autoimmunity (Suppl ): 33

Titus, T.; Badet, L.; Mc Shane, P.; Smith, R.A.G.; Gray, D.W.R. 2001: APT070 a novel membrane targeted C3 convertase inhibitor, attenuates islet damage in an in vitro model of hyperacute pancreatic islet xenograft rejection. Molecular Immunology 38(2-3): 125

Shaw, J.; Bott, M.; Johnson, R.; Ivor, L.; Light, J.; Mauricio, M.; Spencer Covill, S. 2002: APTIMA CT assay Chlamydia trachomatis diagnostic or confirmation applications in one assay. International Journal of STD and AIDS 13(Suppl 1): 37

Pate, M.S.; Hook, E.W.IIi; Martin, D.H.; Willis, D.; Schachter, J.; Gaydos, C.; Quinn, T.C.; Weissfeld, A.; Ferrero, D. 2001: APTIMA combo 2 A new assay for detection of C trachomatis in men. International Journal of STD and AIDS 12(Suppl 2): 116

Bott, M.; Bixby, T.; Castillo, M.; Light, J.; Smith, M.; Spencer Covill, S.; Turner, S.; Watson, M.; Williams, R.; Shaw, J. 2001: APTIMATM Combo 2 analytical performance with C trachomatis and N gonorrhoeae. International Journal of STD and AIDS 12(Suppl 2): 97-98

Zoran, M.; Coen, D.; Bronic, A. 2001: APTT in patients on LMWH prophylaxis. Clinical Chemistry and Laboratory Medicine 39(Special Suppl): S269

Toh, C.H. 1999: APTT revisited: detecting dysfunction in the hemostatic system through waveform analysis. Thrombosis and Haemostasis 82(2): 684-687

Toh, C.H.; Downey, C.; Hargreaves, D.; Robin, N. 1999: APTT waveform analysis and prediction of mortality in the critical care setting. British Journal of Haematology 105(Suppl 1): 47

Haj Ichya, S.; Sherer, Y.; Blank, M.; Shoenfeld, Y. 2002: APTs induce thrombosis in an animal model of APS. Lupus 11(9): 550

Raikhlin, N.; Smirnova, E.; Probatova, N.; Bebezov, B.; Badaljan, X.; Tschistjakova, O.; Bronstein, M.; Bukaeva, I.; Baronin, A. 2001: APUD-system tumours Ultrastructural diagnosis and prognosis. Virchows Archiv 439(3): 389-390

Ravaglia, S.; Bini, P.; Chimento, P.; Costa, A.; Moglia, A. 2003: APoE genotype and nongenetic risk factors Interactions in Alzheimers disease. European Journal of Neurology 10(Suppl 1): 235

Etnier, J.L.; Sibley, B.A.; Caselli, R.J.; Tessier, D. 2003: APoE-4 genotype and aerobic fitness as predictors of cognitive decrements in older women. Medicine and Science in Sports and Exercise 35(5 Suppl): S25

Hudson, R.A. 2000: AQ10 biofungicide A case study in the commercialization of biological control agents. Phytopathology 90(6 Suppl): S101

Agren, J.; Zelenin, S.; Hakanson, M.; Eklof, A.C.; Nielsen, S.; Aperia, A.; Sedin, G. 2000: AQP 3 expression in perinatal rat skin Relation to age, skin barrier function and antenatal corticosteroid treatment. Acta Physiologica Scandinavica 170(4): A44-A45

Valenti, G.; Procino, G.; Annamaria, D'alessandro; Francesco, A.; Laera, A.; Rigamonti, W.; Della Vella, M.; Montini, G.; Zacchello, G.; Svelto, M.; Murer, L. 2003: AQP2 downregulation in human congenital obstructive nephrouropathy. Journal of the American Society of Nephrology 14(Abstracts Issue): 310A

Marchini, G.; Kankes, K.; Stabi, B.; Lonne Rahm, S.; Nielsen, S. 2003: AQP3-expressing immune cells in erythema toxicum neonatorum A possible role in immunosurveillance at birth. Pediatric Research 53(4 Part 2): 363A

Nejsum, L.N.; Kwon, T.H.; Fumagelli, O.; Frokiaer, J.; Agre, P.; Menon, A.G.; Krane, C.M.; Nielsen, S. 2001: AQP5 is present in the apical plasma membrane of rat and mouse sweat glands, and mice deficient of AQP5 have significantly reduced sweat secretion. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 62A

Colombo, C.; Barbetti, F.; Pavan, W.; Reitman, M. 2003: AQTLon chromosome 1 regulates glucose level, triglyceride level, liver weight and body weight in lipoatrophic mice. Diabetes 52(Suppl 1): A249

Nelson, R.M.; Hainsworth, A.H.; Lambert, D.G.; Jones, J.A.; Murray, T.K.; Cross, A.J.; Green, A.R. 2000: AR-A008055, a clomethiazole analogue, is neuroprotective in a global ischaemia model in vivo and inhibits ischaemia-induced glutamate release in vitro. British Journal of Pharmacology 131(Proceedings Suppl December): 204P

Warmoth, K.; Trujillo, K.A.; Ruzek, E.; Glen, R.; Smith, J.; Thomsen, W.; Behan, D.P.; Chalmers, D.T. 1999: AR116,102, a novel high affinity 5HT2A receptor inverse agonist with in vivo efficacy. Society for Neuroscience Abstracts 25(1-2): 1201

Ueda, T.; Yamaguchi, M.; Uchimiya, H.; Nakano, A. 2001: ARA6, a plant-unique RAB/YPT GTPase involved in the regulation of endocytic function in Arabidopsis thaliana. Cell Structure and Function 26(5): 396

Zhao, L.; Hu, Y.; Chong, K.; Wang, T. 2010: ARAG1, an ABA-responsive DREB gene, plays a role in seed germination and drought tolerance of rice. Annals of Botany 105(3): 401-409

Guo, D.F.; Hamet, P.; Orlov, S.N. 2000: ARAP1, a novel angiotensin II type 1 receptor associated protein, binds and recycles the receptor to the plasma membrane. Canadian Journal of Cardiology 16(Suppl F): 125F

Shelke, R.R.J.; Dirks, A.J.; Leeuwenburgh, C. 2002: ARC an inhibitor of apoptosis is expressed in the rat brain and is increased with caloric restriction. FASEB Journal 16(4): A140

Li, J.; Li, P.; Von Harsdorf, R. 2001: ARC blocks p53-induced cardiomyocyte apoptosis through inhibiting the activation of caspase-3 and caspase-9 but independent of cytochrome c. Circulation 104(17): 2; 293

Courtney, U.M. 2002: ARC breast cancer partners programme A psychoeducative programme for men. European Journal of Cancer 38(Suppl 3): S76-S77

Courtney, U.M. 2001: ARC breast cancer partners support programme. European Journal of Cancer 37(Suppl 6): S397

Courtney, U.M. 2001: ARC support services in cancer care in Ireland. European Journal of Cancer 37(Suppl 6): S439

Howells, R.; Calvin, J.; Karet, F.; Firth, H.; Ramaswami, U. 2001: ARC syndrome Heterogeneity in liver dysfunction. Journal of Inherited Metabolic Disease 24(Suppl 1): 151

Gissen, P.; Johnson, C.A.; Stapelbroek, J.; Mckieman, P.J.; Thompson, R.J.; Houwen, R.; Kelly, D.A.; Maher, E.R. 2003: ARC syndrome is not allelic to PFIC 1 and 2. Journal of Medical Genetics 40(Suppl 1): S64

Hofler, J.G.; Kettlety, T.R.; Wolaniuk, D.L.; Smith, S.B.; Schmidt, E.M.; Smith, G.A.; Covert, W.E.; Friese, J.A. 2004: ARCHITECT CA 15-3, a chemiluminescent assay. Clinical Chemistry 50(6, Suppl S, Part 2): A82

Kuemmerle Deschner, J.B.; Bergmann, J.; Ihle, J.; Orlikowski, T.; Dannecker, G.E. 1999: ARDIS - arthritis and rheumatism database and information system. Arthritis and Rheumatism 42(9 Suppl): S327

Stoeck, T.; Welter, H.; Seitz Bender, D.; Kusch, J.; Schmidt, H.J. 2000: ARDRA and RAPD-fingerprinting reject the sibling species concept for the ciliate Paramecium caudatum. Zoologica Scripta 29(1): 75-82

Wiedermann, F.J.; Lederer, W.; Sepp, N.; Schobersberger, W. 2001: ARDS in catastrophic antiphospholipid syndrome. Lupus 10(5): 382-383

Cerf, C.; Leroux, B.; Reynaud, P.; Duvaldestin, P.; Dhonneur, G. 1999: ARDS risk-factors after pulmonary contusions. Anesthesiology 91(3A): A231

Zhang, T.; Kruys, V.; Huez, G.; Gueydan, C. 2002: ARE-mediated translational control Complexity and multiple activities of trans-activating factors. Biochemical Society Transactions 30(5): A116

Yoshida, T.; Fujita, Y.; Sayama, H.; Kidokoro, S.; Maruyama, K.; Mizoi, J.; Shinozaki, K.; Yamaguchi-Shinozaki, K. 2010: AREB1, AREB2, and ABF3 are master transcription factors that cooperatively regulate ABRE-dependent ABA signaling involved in drought stress tolerance and require ABA for full activation. Plant Journal: for Cell and Molecular Biology 61(4): 672-685

Mcpherson, E. 2000: AREDYLD syndrome with focal segmental glomerulosclerosis. Genetics in Medicine 2(1): 82

Cockcroft, S.; Jones, D. 1999: ARF, a multi-functional GTPase as a co-ordinator of membrane traffic - Is ARF-regulated phospholipase D the answer to everything?. Biochemical Society Transactions 27(3): A75

Sherr, C.J.; Quelle, D.E. 2001: ARF-p19, a novel regulator of the mammalian cell cycle. Official Gazette of the United States Patent and Trademark Office Patents 1242(2)

Sherr, C.J.; Zindy, F.; Kamijo, T.; Weber, J.D.; Eischen, C.M.; Diehl, J.A.; Randle, D.; Chong, M.; Cleveland, J.L.; Mckinnon, P.J.; Zambetti, G.; Roussel, M.F. 1999: ARF-p53 pathway in tumor surveillance. Proceedings of the American Association for Cancer Research 40: 775

Spang, A. 2002: ARF1 regulatory factors and COPI vesicle formation. Current Opinion in Cell Biology 14(4): 423-427

Palacios, F.; D'souza Schorey, C. 2000: ARF6 regulates adherens junction assembly in epithelial cells. Molecular Biology of the Cell 11(Suppl): 115a-116a

Bettandorff, J.A.; Delaney, K.A.; Radhakrishna, H. 2000: ARF6 regulates the non clathrin-dependent trafficking of m2 muscarinic acetylcholine receptors. Molecular Biology of the Cell 11(Suppl): 507a-508a

Galkin, V.E.; Orlova, A.; Koleske, A.J.; Egelman, E.H. 2004: ARG kinase uses multiple modes to bind F-actin. Biophysical Journal 86(1): 68a

Varret, M.; Abifadel, M.; Villeger, L.; Robin, A.; Allard, D.; Devillers, M.; Rabes, J.P.; Junien, C.; Boileau, C. 2002: ARH and HCHOLA3 Two different genes at 1p both implicated in familial hypercholesterolemia. American Journal of Human Genetics 71(4 Suppl): 443

Zlotogora, J. 2002: ARH mutations and hypercholesterolaemia in Sardinia. Lancet 360(9338): 1024; Author Reply 1024

Xu, F.; Yu, Y.H. 2000: ARHI , an imprinted tumor suppressor gene, was lost in bladder and prostate carcinomas. Proceedings of the American Association for Cancer Research 41: 779

Bao, J.J.; Le, X.F.; Wang, R.Y.; Andreeff, M.; Yu, Y.; Bast, R.C. 2002: ARHI induces apoptosis through a caspase-independent pathway. Proceedings of the American Association for Cancer Research 43: 620

Yu, Y.; Xu, F.J.; Xia, W.; Zhao, S.; Peng, H.Q.; Luo, R.Z.; Long, Y.; Parlow, A.F.; Hung, M.C.; Bast, R.C. 2000: ARHI inhibits the production of PRL and progesterone, induces the defects of ovary and mammary gland development in transgenic mice. Proceedings of the American Association for Cancer Research 41: 227

Yu, Y.H.; Peng, H.Q.; Xu, F.J.; Fang, X.J.; Zhao, S.L.; Huang, Z.; Thornton, A.; Devers, M.; Kuo, W.L.; Gray, J.W.; Mills, G.B.; Bast, R.C.Jr 1999: ARHI is an imprinted tumor suppressor gene on 1p31. Proceedings of the American Association for Cancer Research 40: 546

Luo, R.Z.; Xianjun, F.; Marquez, R.; Liu, S.Y.; Mills, G.B.; Liao, W.S.L.; Yu, Y.; Bast, R.C.J. 2003: ARHI is an unusual Ras family member that inhibits growth and constitutively binds GTP in resting cells. Proceedings of the American Association for Cancer Research 44: 594

Lockey, R.F. 2001: "ARIA": global guidelines and new forms of allergen immunotherapy. Journal of Allergy and Clinical Immunology 108(4): 497-499

Klossek, J.; Neukirch, F.; Gehanno, P.; Bodez, T.; Liard, F.; Janin, N.; Bousquet, J. 2004: ARIA guidelines for allergic rhinitis in specialist practices A randomized controlled trial with ebastine. Journal of Allergy and Clinical Immunology 113(2 Suppl): S26

Kortschak, R.D.; Tucker, P.W.; Saint, R. 2000: ARID proteins come in from the desert. Trends in Biochemical Sciences 25(6): 294-299

Kotaja, N.; Aittomaki, S.; Silvennoinen, O.; Palvimo, J.J.; Janne, O.A. 2000: ARIP3 and other PIAS proteins differ in their ability to modulate steroid receptor-dependent transcriptional activation. Molecular Endocrinology 14(12): 1986-

Rouleau, N.; Moilanen, A.M.; Palvimo, J.J.; Janne, O.A. 2004: ARIP4 gene and protein. Official Gazette of the United States Patent and Trademark Office Patents 1279(3)

Murray, T.K.; Wiernicki, T.R.; Mccarty, D.R.; Hicks, C.A.; Dell, C.P.; Patrick, K.E.; Ward, M.A.; Osborne, D.J.; Roman, C.R.; Lodge, D.; Fleisch, J.H.; Singh, J.; O'neill, M.J. 1999: ARL17477, a selective neuronal nitric oxide synthase inhibitor, with neuroprotective effects in animal models of global and focal cerebral ischaemia. Society for Neuroscience Abstracts 25(1-2): 1842

Feltner, M.E. 2003: ARM action alters bicep femoris and rectus femoris activity during countermovement vertical jumps. Medicine and Science in Sports and Exercise 35(5 Suppl): S323

Karimi, M.; Porceddu, A.; Mironov, V.; Van Montagu, M.; Inze, D.; Gheysen, G. 1999: ARM1 Application for engineered resistance to plant-parasitic nematodes. Mededelingen van de Faculteit Landbouwwetenschappen - Rijksuniversiteit Gent 64(5B): 439-442

Montalescot, G.; Drouet, L. 2001: ARMADA study A randomized comparison of enoxaparin, dalteparin and unfractionated heparin on markers of cell activation in patients with unstable angina. European Heart Journal 22(Abstract Suppl): 663

Richer, S.P. 1999: ARMD Pilot environmental intervention data. IOVS Investigative Ophthalmology and Visual Science 40(4): S313

Richer, S.P.; Statkute, L.; Stiles, W.; Rudy, D.R.; Karofty, K. 2000: ARMD-serum iron, % transferrin and ferritin data. IOVS Investigative Ophthalmology and Visual Science 41(4): S159

Lui, H.M.; Naumovski, L. 2002: ARMER protects cells against apoptosis. Proceedings of the American Association for Cancer Research 43: 998

Dworniczak, B.; Vorobyov, E.; Kondrashov, A.; Juelich, A.; Dockhorn Dworniczak, B.; Horst, J. 1999: ARMS Identification of novel differentially expressed genes. Modern Pathology 12(1): 10A

Callaghan, K.; Howes, N.; Greenhalf, W.; Neoptolemos, J.P.; Fox, J.C. 1999: ARMS detection in real time of under- represented mutant K-ras sequence in patients at risk of pancreatic cancer. British Journal of Cancer 80(Suppl 2): 83

Altschuler, Y.; Santy, L.; Frank, S.; Avrahami, D.; Li, Y.W.; Casanova, J.; Mostov, K. 2000: ARNO and ARF6 regulate endocytosis at the apical surface of polarized epithelial cells. Molecular Biology of the Cell 11(Suppl): 324a-325a

Greenwood, R.; Nicholas, R. 2002: ARO1 multifunctional polypeptide of Candida albicans. Official Gazette of the United States Patent and Trademark Office Patents 1255(2)

Mueller, A.; Moser, M.; Leder, S.; Kluge, R.; Joost, H.G.; Schuermann, A. 2001: ARP is essential for the embryonic development of mice. Naunyn-Schmiedeberg's Archives of Pharmacology 363(4): R59

Eldor, A.; Grisaru, D.; Deutsch, V.; Shapira, M.; Sternfeld, M.; Melamed Book, N.; Kaufer, D.; Galyam, N.; Lessing, J.B.; Soreq, H. 2000: ARP, a 26-residue peptide cleaved from acetylcholinesterase, modulates blood cell composition under stress and acts as a hematopoietic growth promoting factor. Acta Haematologica (Basel) 103(Suppl 1): 2

Swanson, J.C. 2002: ARPAS animal care certification program. Journal of Dairy Science 85(Suppl 1): 168

Tao, W.; Rein, D.H.; Dean, B.J.; Stabila, P.F.; Goddard, M.B.I. 2002: ARPE-19 as a platform cell line for encapsulated cell-based delivery. Official Gazette of the United States Patent and Trademark Office Patents 1256(4)

Nurnberger, J.; Miller, K.J.; Wang, J.; Sanford, M.; Bacallao, R.L.; Phillips, C.L. 2001: ARPKD and inversin Isoforms and cellular distributions. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 542A